Introduction {#s1}
============

Hepatocyte nuclear factor 4alpha (HNF4α) (NR2Α1) is a highly conserved member of nuclear receptor superfamily of ligand-dependent transcription factors that is expressed in liver, kidney, pancreas, stomach and intestine ([@bib64]). HNF4α is best known for its role in the liver where it is a master regulator of liver-specific gene expression and essential for adult and fetal liver function ([@bib35]; [@bib43]; [@bib8]; [@bib56]). HNF4α is also known for its role in the pancreas where it regulates insulin secretion from beta cells ([@bib32]; [@bib33]; [@bib50]). Mutations in the *HNF4Α* gene and promoter regions are associated with Maturity Onset Diabetes of the Young 1 (MODY1) ([@bib25]).

In contrast, the role of HNF4α in the intestine has only recently been investigated. Knockout of the *Hnf4a* gene in the embryonic mouse colon results in disrupted crypt topology, and a decreased number of epithelial and mature goblet cells ([@bib30]), while the adult intestinal knockout shows defects in the balance between proliferation and differentiation as well as immune function, ion transport, epithelial barrier function and oxidative stress ([@bib1]; [@bib12]; [@bib17]; [@bib18]; [@bib13]). Dysregulation of the *HNF4A* gene is linked to several gastrointestinal disorders including colitis and colon cancer and a single nucleotide polymorphism in the *HNF4A* gene region is associated with ulcerative colitis ([@bib1]; [@bib15]; [@bib68]; [@bib57]; [@bib5]).

While it is clear that HNF4α is critical for normal colon function, it is not known which transcript variant is the most relevant. There are two different promoters (proximal P1 and distal P2) in the HNF4α gene that are both active in the colon. The promoters are conserved from frog to human and, along with alternative splicing, give rise to nine different transcript variants of HNF4α ([@bib41]) ([Figure 1A](#fig1){ref-type="fig"}). The major isoforms of the P1 promoter are HNF4α1/α2 while the P2 promoter gives rise to HNF4α7/α8: distinct first exons result in an altered A/B domain which harbors the activation function 1 (AF-1) while the DNA and ligand binding domains are identical. The two promoters are expressed under unique temporal and spatial conditions, with the large and small intestine being the only adult tissues that express both P1- and P2-HNF4α ([@bib68]; [@bib53]). While a loss of P1- but not P2-HNF4α has been noted in colon cancer ([@bib15]; [@bib68]), the specific roles of the HNF4α isoforms remain obscure. For example, P1-driven HNF4α acts as a tumor suppressor in mouse liver ([@bib34]; [@bib72]). In contrast, the *HNF4A* gene and protein are amplified in human colon cancer ([@bib11]; [@bib76]) although the different isoforms were not distinguished in those studies. We recently showed that ectopic expression of P1- but not P2-HNF4α decreased the tumorigenic potential of the human colon cancer cell line HCT116 in a mouse xenograft model ([@bib71]), suggesting that the different HNF4α isoforms may indeed play distinct roles in the colon.

Here, we investigate the role of P1- and P2-HNF4α isoforms in the mouse colon using genetically engineered mice that express either the P1- or the P2-HNF4α isoforms ([@bib10]). We show that in wildtype (WT) mice P1- and P2-HNF4α are expressed in different compartments in the colonic epithelium, interact with distinct sets of proteins, regulate the expression of unique sets of target genes, and play distinct roles during pathological conditions such as colitis and colitis-associated colon cancer (CAC). We also provide genetic and biochemical evidence indicating that RELMβ, a member of the RELM/FIZZ family of cytokines, plays a critical role in the response of HNF4α to colitis and appears to be both directly and indirectly regulated by HNF4α.

Results {#s2}
=======

Compartmentalization of P1- and P2-HNF4α in mouse colonic epithelium {#s2-1}
--------------------------------------------------------------------

In the distal colon, the bottom two-thirds of the crypt and the top one-third, including surface epithelium, are functionally categorized as proliferative and differentiated compartments, respectively ([@bib59]). We used monoclonal antibodies specific to the different HNF4α isoforms ([@bib15]; [@bib68]) ([Figure 1A](#fig1){ref-type="fig"}) to examine the distribution of P1- and P2-HNF4α along the crypt-surface axis. The P1/P2 antibody, which recognizes both P1- and P2-HNF4α, shows HNF4α expression in both crypt and surface epithelial cells ([Figure 1B](#fig1){ref-type="fig"}), as reported previously ([@bib1]; [@bib17]; [@bib13]). In contrast, the isoform-specific antibodies reveal that P1-HNF4α is expressed mainly in the differentiated compartment, not in the proliferative compartment as defined by NKCC1 staining ([Figure 1C](#fig1){ref-type="fig"}). P2-HNF4α was observed primarily in the bottom half of the crypt ([Figure 1B](#fig1){ref-type="fig"}) and co-localized with the proliferation marker Ki67 in isolated colonic crypts ([Figure 1D](#fig1){ref-type="fig"}). While there was some expression of P2-HNF4α in the differentiated compartment (i.e., non Ki67 expressing cells), it was notably absent from the surface epithelium ([Figure 1B](#fig1){ref-type="fig"}).10.7554/eLife.10903.003Figure 1.Differential localization of HNF4α isoforms in mouse colonic crypts.(**A**) Schematic of the mouse (and human) *Hnf4a* gene showing the two promoters (P1 and P2) (top) and the P1- and P2-driven HNF4α isoforms that they express (bottom). The differential N-terminal A/B domain (indicated in blue and orange) as well as epitopes to isoform-specific (αP1 and αP2) and common (αP1/P2) antibodies are indicated. DBD, DNA binding domain; LBD, ligand binding domain; F, F domain. (**B**--**D**) IF and immunohistochemistry of distal colon (**B**,**C**) or isolated colonic crypts (**D**) stained for the indicated proteins using the antibodies in (**A**) (**B**: 40X magnification; **C**,**D**: 25X magnification with digital zoom). NKCC1 (*Slc12a2*) (**C**) and Ki67 (**D**) mark the proliferative compartment of the crypt. Representative images from two independent experiments (n=2--4 mice per genotype) are shown.**DOI:** [http://dx.doi.org/10.7554/eLife.10903.003](10.7554/eLife.10903.003)

Isoform-specific dysregulation of HNF4α in mouse models of colitis and colon cancer {#s2-2}
-----------------------------------------------------------------------------------

Previous studies showed that *HNF4A* expression is decreased in human inflammatory bowel disease (IBD) patients and intestine-specific deletion of the mouse *Hnf4a* gene increases susceptibility to dextran sodium sulfate (DSS)-induced colitis ([@bib1]) and can lead to chronic inflammation even in the absence of DSS ([@bib17]). However, these studies do not address the role of the individual HNF4α isoforms. We treated young adult male mice (WT) with 2.5% DSS and found a statistically significant decrease in total HNF4α following 5 days of DSS treatment, as others have observed ([@bib1]; [@bib13]), and an increase in HNF4α during the recovery phase, especially P1-HNF4α ([Figure 2A,B](#fig2){ref-type="fig"}). Contrary to the restricted expression of P1-HNF4α in the differentiated compartment in untreated mice, P1-HNF4α was also expressed near the bottom of the crypt after DSS treatment ([Figure 2C](#fig2){ref-type="fig"}), consistent with substantial loss of proliferating cells following DSS treatment ([@bib69]). 10.7554/eLife.10903.004Figure 2.Dysregulation of P1- and P2-HNF4α in mouse models of colitis and colon cancer.(**A**) IB of WCE from the distal colon of WT mice treated with 2.5% DSS for 5 days followed by 0 or 3 days recovery, and an analogous region of untreated (Control) mice. Each lane is from a different mouse. The position of the molecular weight marker (52 kD) is shown. (**B**) Quantification of the HNF4α signal in (**A**) normalized to total protein, as determined by Coomassie staining of the same blot. For the purposes of quantification the outlier in lane 8 was omitted. \**P*\<0.05, \*\**P*\<0.005. (**C**) Representative IF of distal colon from untreated and DSS-treated WT mice (n=3--4 per condition) stained with P1-HNF4α antibody (40X magnification). Arrow indicates P1-HNF4α expressing cells near the bottom of the crypt in the DSS-treated mice. (**D**) IB as in (**A**) but from the tumor area of WT mice treated with 10 mg/kg AOM and three cycles of a 7-day DSS treatment and harvested at \~95 days. Three gels were run in parallel with the same extracts; one representative β-actin stain is shown. (**E**) IB analysis as in (**D**) but from mice injected six times with 10 mg/kg AOM and harvested at \~150 days. Shown is one representative of the three Coomassie stains performed for loading verification.**DOI:** [http://dx.doi.org/10.7554/eLife.10903.004](10.7554/eLife.10903.004)

In a mouse model of colitis-associated colon cancer (CAC) in which a single injection of azoxymethane (AOM) is followed by multiple treatments of DSS in the drinking water, we found that P1-HNF4α is greatly reduced in tumors compared to untreated controls but that total HNF4α protein was only marginally reduced ([Figure 2D](#fig2){ref-type="fig"}), suggesting that P2-HNF4α was not affected. The P1-HNF4α decrease correlated with an increase in active Src (pSrc), consistent with our earlier finding that Src specifically phosphorylates and causes the degradation of human P1- but not P2-HNF4α ([@bib15]). We also observed a specific loss of P1-HNF4α protein in a mouse model of sporadic, non-colitis colon cancer ([Figure 2E](#fig2){ref-type="fig"}), as we observed previously in humans ([@bib15]).

Differential susceptibility of HNF4α isoform-specific mice to colitis-associated colon cancer {#s2-3}
---------------------------------------------------------------------------------------------

To decipher the function of the HNF4α isoforms in the colon, we utilized HNF4α isoform-specific mice generated by an exon swap strategy ([Figure 3A](#fig3){ref-type="fig"} top left) ([@bib10]). These mice express exclusively either P1-HNF4α (α1HMZ) or P2-HNF4α (α7HMZ) wherever HNF4α is endogenously expressed. Immunoblot analysis confirmed that the HNF4α protein level in the distal colon of the exon swap mice is equivalent to that of WT littermates, and that P2-HNF4α is the major isoform in the distal colon ([Figure 3A](#fig3){ref-type="fig"} top right and [Figure 3---figure supplement 1E](#fig3s1){ref-type="fig"}). In α1HMZ mice, P1-HNF4α was detected in all epithelial cells in both the bottom of the crypt and the surface epithelium; a similar ubiquitous expression was observed for P2-HNF4α in α7HMZ mice ([Figure 3A](#fig3){ref-type="fig"} bottom).10.7554/eLife.10903.005Figure 3.Differential susceptibility of HNF4α isoform-specific mice to colitis-associated colon cancer.(**A**) Top left, Schematic of *Hnf4a* exon-swap (i.e., isoform-specific) mice. Top right, IB as in [Figure 2A](#fig2){ref-type="fig"} of WCE from the distal colon of the exon-swap mice and their WT controls, probed with the common αP1/P2 antibody. See [Figure 3---figure supplement 1E](#fig3s1){ref-type="fig"} for verification of protein loading. Bottom, representative IF of distal colons from untreated α1HMZ and α7HMZ mice stained with either P1- or P2-driven HNF4α specific antibodies (40X magnification). N=3--4 mice per genotype examined. Scale for P1-HNF4α α1HMZ is 0.22 x 0.22 microns; all others are 0.36 x 0.36 microns. (**B**) Tumor growth in WTα1 (n = 5) and α1HMZ (n = 6) mice treated with 10 mg/kg AOM and two cycles of DSS (5 days per cycle) and harvested at \~53 days. Right, number of tumors per mouse colon. Left, tumor load (sum of the width or length of all macroscopic lesions in a given mouse). Each symbol represents results from one mouse. (**C**) Left, average length of crypt in WTα1 and α1HMZ mice, untreated (Control) or treated as in (**B**) N = 2--3 mice per condition; 26--56 crypts per mouse were measured. \**P*\<0.0005 between treated and control within a genotype and across genotypes in the treated condition. Right, Representative H&E stain (10X magnification) of mice treated as in (**B**) Scale bar is 100 microns. (**D**) Tumor number in WTα1 (n = 15) and α1HMZ (n = 17) male mice treated as in (**B**) but with three cycles of DSS (two cycles of 5 days and one cycle of 4-days) and harvested at \~85 days. Top, total number of tumors per mouse. Bottom, number of tumors per mouse based on the tumor width. n.s., non-significant. (**E**) As in (**B**) but for WTα7 (n = 21) and α7HMZ (n = 23) mice treated with 10 mg/kg AOM and 2--3 cycles of DSS (4--5 days per cycle) and harvested at \~53--64 days. *P-*values between α7HMZ and WTα7 mice are indicated. Tumor data were pooled from three independent experiments. (**F**) Tumor number and load in WTα7 (n = 20) and α7HMZ (n = 14) mice as in (**E**) but harvested at \~85 days. The following figure supplement is available for [Figure 3](#fig3){ref-type="fig"}:**DOI:** [http://dx.doi.org/10.7554/eLife.10903.005](10.7554/eLife.10903.005)10.7554/eLife.10903.006Figure 3---figure supplement 1.HNF4α isoform-specific mice subjected to AOM+DSS to induce colitis-associated colon cancer.(**A**) Spleen-to-body weight ratio of WTα1 (n=5) and α1HMZ (n=6) mice treated with 10 mg/kg AOM and two cycles of DSS (5 days per cycle) and harvested at \~54 days. (**B**) Tumor load in WTα7 and α7HMZ male mice treated with 10 mg/kg AOM and 2--3 cycles of DSS (4--5 days per cycle) and harvested after different time points as indicated. Each symbol represents results from one mouse. (**C**) IF of Ki67 (green) and nuclear (red) staining in the distal colon of treated (10 mg/kg AOM and 2 cycles of DSS, 5 days) WTα7 and α7HMZ male mice harvested at 53--64 days. (**D**) Average percent of Ki67-positive cells counted in two to three fields in (C) from mice (n=2-4) per condition (\~2300 to 3000 total cells per genotype scored). n.s., not statistically significant. (**E**) IB from [Figure 3A](#fig3){ref-type="fig"} in main text with Coomassie stain to show equal loading.**DOI:** [http://dx.doi.org/10.7554/eLife.10903.006](10.7554/eLife.10903.006)

After 53 days of AOM+DSS treatment, the α1HMZ mice had significantly fewer and smaller tumors compared to WT controls ([Figure 3B](#fig3){ref-type="fig"}). In addition, despite similar crypt length in untreated WT and α1HMZ mice, the α1HMZ mice did not exhibit the characteristic increase in crypt length associated with mutagen exposure observed in WT mice ([@bib61]) ([Figure 3C](#fig3){ref-type="fig"}). In fact, the crypt length decreased compared to both treated WT and untreated α1HMZ. We also observed fewer infiltrating immune cells ([Figure 3C](#fig3){ref-type="fig"} right) as well as decreased spleen-to-body weight ratio in the treated α1HMZ mice ([Figure 3---figure supplement 1A](#fig3s1){ref-type="fig"}). After 85 days of treatment, the difference in tumor number was less pronounced: a significant decrease in tumor number was observed in α1HMZ mice only in the smallest tumors (0--2 mm) ([Figure 3D](#fig3){ref-type="fig"}).

In contrast to α1HMZ mice, the α7HMZ mice exhibited a greater tumor load and tumor number than their WT controls after 53--64 days of treatment ([Figure 3E](#fig3){ref-type="fig"}). However, at the later time point (85 days), the effect was lost mainly due to increased tumor burden in the WT mice ([Figure 3F](#fig3){ref-type="fig"} and [Figure 3---figure supplement 1B](#fig3s1){ref-type="fig"}). Interestingly, there was no difference in the percent of Ki67-staining cells between WT and α7HMZ mice (53--64 day treatment) ([Figure 3---figure supplement 1C,D](#fig3s1){ref-type="fig"}).

Differential susceptibility of HNF4α isoform-specific mice to colitis {#s2-4}
---------------------------------------------------------------------

More striking than tumor induction by AOM+DSS in the α1HMZ and α7HMZ mice was their response to an acute DSS treatment to induce colitis \--2.5% DSS in drinking water for 5 days. There was a \~73% mortality rate for α7HMZ mice that occurred starting after three days of recovery when the mice were switched to normal tap water ([Figure 4A](#fig4){ref-type="fig"}). During the recovery phase, α7HMZ mice exhibited a significant decrease in body weight and colon length ([Figure 4B](#fig4){ref-type="fig"} and [Figure 4---figure supplement 1A](#fig4s1){ref-type="fig"}), and a worse histological score (due to more severe crypt damage, inflammation and ulceration) compared to their WT littermates ([Figure 4C](#fig4){ref-type="fig"} and [Figure 4---figure supplement 1B](#fig4s1){ref-type="fig"}). There was also an increased spleen-to-body weight ratio ([Figure 4---figure supplement 1C](#fig4s1){ref-type="fig"}) when the mice were maintained and treated in an open access vivarium. IB analysis revealed that, in contrast to the WT mice that lost expression of both HNF4α isoforms after five days of DSS and then had an increase in P1-HNF4α expression at 3-day recovery ([Figure 2A](#fig2){ref-type="fig"}), in the α7HMZ mice P2-HNF4α protein amount is notably increased upon DSS treatment and then decreased after a 3-day recovery, as observed by both IB and IF ([Figure 4D](#fig4){ref-type="fig"}). At 12 days of recovery, we observed a massive infiltration of immune cells and a continued striking loss in crypt structure in α7HMZ mice compared to WT mice ([Figure 4---figure supplement 1D](#fig4s1){ref-type="fig"}).10.7554/eLife.10903.007Figure 4.Differential susceptibility of HNF4α isoform-specific mice to DSS-induced colitis.(**A**) Percent mortality of WTα7 (n = 28) and α7HMZ (n = 16) mice treated with 2.5% DSS for 5 days. α7HMZ mice typically died during day 3 to 12 of recovery following DSS treatment. Data pooled from two independent experiments. Not shown is a third experiment with older mice (21--23 weeks) with similar results (WT: 1 of 5 mice died; α7HMZ: 3 of 6 mice died). (**B**) Change in bodyweight (represented as% initial body weight) (left) and colon length (right) of WT (n = 4) and α7HMZ (n = 4) mice treated as indicated. Significant comparisons are indicated with a *P*-value. (**C**) Left, representative H&E stain of WT and α7HMZ mice treated with 2.5% DSS for 5 days followed by 0 or 3 days of recovery. Right, histological scores of colitis in WTα7 (n = 4) and α7HMZ (n = 4) mice. (**D**) Left, IB for HNF4α (P1/P2 antibody) of WCE from the distal colon of α7HMZ mice treated as indicated. Right, representative IF of distal colon from α7HMZ mice treated with 2.5% DSS for 5 days -/+ recovery as indicated and stained with P1/P2-HNF4α antibody (green) and TO-PRO3 (red) for nuclei (40X magnification). Extracts from four mice per genotype (out of n = 5--7) were randomly chosen for IB analysis on a single gel/blot; sections from 3 mice per genotype were examined. (**E**) Colon length of WT (n = 8) and α1HMZ (n = 10) male mice treated with 2.5% DSS for 5 days followed by 3 days of recovery. Results from two independent experiments were pooled. (**F**) Representative H&E stain (left) and histological scores (right) of colitis in WTα1 (n = 8) and α1HMZ (n = 10) mice treated as in (**E**). The following figure supplements are available for [Figure 4:](#fig4){ref-type="fig"}**DOI:** [http://dx.doi.org/10.7554/eLife.10903.007](10.7554/eLife.10903.007)10.7554/eLife.10903.008Figure 4---figure supplement 1.Increased susceptibility of α7HMZ mice to DSS-induced colitis.Results from an independent DSS experiment from that shown in Figure 4 A-C. Mice from this experiment were analyzed by IB and IF in Figure 4D. (**A**) Colon length of WTα7 and α7HMZ mice treated with 2.5% DSS for 5 days followed by 0 or 3 days of recovery. \**P*\<0.001, between WTα7 and α7HMZ at 3 days of recovery. N=4--7 per genotype per treatment. (**B**) Representative H&E stain of distal colon of WTα7 and 7HMZ mice treated in (**A**). (**C**) Spleen-to-body weight ratio of WT7 (n=7) andα7HMZ (n=5) mice treated with 2.5% DSS for 5 days and sacrificed the following day. (**D**) Representative H&E stain of distal colon from WTα7 and α7HMZ mice treated with 2.5% DSS for 5 days followed by 12 days of recovery. N=5 per genotype treated, 2--3 mice sectioned.**DOI:** [http://dx.doi.org/10.7554/eLife.10903.008](10.7554/eLife.10903.008)10.7554/eLife.10903.009Figure 4---figure supplement 2.Increased inflammation in α7HMZ mice in DSS-induced colitis.(**A**) Spleen-to-body weight ratio of α7HMZ (n=7) and α1HMZ (n=7) mice treated for 4 days with 2.5% DSS followed by 18 days of recovery. (**B**) Crypt length of α7HMZ (n=3) and α1HMZ (n=3) mice treated as in (**A**): 26-37 crypts analyzed per genotype. (**C**) Representative photographs of colons from α7HMZ and α1HMZ mice treated with 2.5% DSS for 4 days and allowed to recover for 18 days. (**D**) Representative H&E stain (10X magnification) of α7HMZ and α1HMZ male mice treated as in (**A**) along with histological score from three mice per genotype.**DOI:** [http://dx.doi.org/10.7554/eLife.10903.009](10.7554/eLife.10903.009)

In contrast to the extreme sensitivity of the α7HMZ mice to DSS-induced colitis, α1HMZ mice were less susceptible than their WT controls as indicated by increased colon length ([Figure 4E](#fig4){ref-type="fig"}) and well-preserved crypt structure and decreased histological score ([Figure 4F](#fig4){ref-type="fig"}). There was no difference in spleen-to-body weight ratio between the α1HMZ mice and WT controls (data not shown).

Clinical and histological changes occurring a few weeks after DSS treatment are referred to as chronic or advanced changes ([@bib58]). To examine chronic effects, we allowed the mice to recover for 18 days after a somewhat milder DSS treatment (4 days) to reduce the mortality of α7HMZ mice. Despite the shorter DSS treatment, after 18 days, the α7HMZ mice still exhibited elevated spleen-to-body weight ratio, increased crypt length, more visibly inflamed colons and immune cell infiltration and overall higher histological scores compared to α1HMZ mice ([Figure 4---figure supplement 2A--D](#fig4s2){ref-type="fig"}).

Transcriptomic and proteomic profile of colons from HNF4α isoform-specific mice {#s2-5}
-------------------------------------------------------------------------------

Expression profiling of the distal colon revealed a significant change in a substantial number of genes in the untreated isoform-specific mice compared to their WT controls ([Figure 5---figure supplement 1A](#fig5s1){ref-type="fig"}). There was an overall greater effect in α1HMZ than α7HMZ mice in terms of the number of dysregulated genes with a large fold change, which could be due to the fact that P1-HNF4α typically has a more potent transactivation function than P2-HNF4α ([@bib23]). On the other hand the number of genes altered at lower fold change was higher in α7HMZ compared to α1HMZ mice, consistent with more P2-HNF4α protein in the distal colon of WT mice than P1-HNF4α ([Figure 3A](#fig3){ref-type="fig"}) . Gene Ontology (GO) analysis of the differentially regulated genes showed that in α1HMZ mice there is a marked upregulation of genes involved in wound healing and immune response, as well as a variety of metabolic processes typically associated with differentiation ([Figure 5A](#fig5){ref-type="fig"}). In contrast, in α7HMZ mice there is a significant upregulation of genes involved in cell cycle and DNA repair and a decrease in genes involved in cell adhesion, motility and ion transport ([Figure 5B](#fig5){ref-type="fig"}). (See [Figure 5---source data 1A](#SD1-data){ref-type="supplementary-material"}-1G for the fold change in the top 100 dysregulated genes and the genes in the aforementioned GO categories, respectively).10.7554/eLife.10903.010Figure 5.Altered gene expression, interacting proteins, migration and ion transport in HNF4α isoform-specific mice.(**A**,**B**) Comparative Gene Ontology (GO) of genes differentially regulated (≥two-fold) in the distal colon of untreated α1HMZ (**A**) and α7HMZ (**B**) mice. (**C**) Top, Venn diagram of total number of HNF4α-interacting proteins from RIME analysis found in α7HMZ only, α1HMZ only or both α7HMZ and α1HMZ colons, as described in Material and methods. Indicated are nuclear proteins that have been implicated in regulating gene expression and associated with human or mouse colon cancer, IBD, Crohn's disease and/or ulcerative colitis, as well as other pro-proliferative proteins found only in α7HMZ colons. Shown also are transcription factors that interact with HNF4α in both genotypes. Bold, proteins mentioned in text. Bottom, Total number of proteins in the indicated categories that show a significant interaction with HNF4α in the exon swap mice. TF, transcription factor; RNA binding proteins; kinase and phosphatase categories include only protein kinases and phosphatases, as well as relevant scaffolding proteins b. (**D**) Untreated HNF4α isoform-specific mice and their WT littermates (n = 3--4 per genotype) were injected with BrdU (75 mg/kg) and sacrificed at 2 hr or 48--50 hr. The distance migrated by the BrdU^+^ cells from the bottom of the crypt between 2 hr and 48--50 hr is plotted as% crypt length; 5--38 crypts per mouse were scored. (**E**) Intestinal chloride secretion in response to 10 µM forskolin and 100 µM carbachol represented as change in short-circuit current (ΔIsc). Left, WTα1 (n = 6) and α1HMZ (n = 5--8) mice. \**P*\<0.02 between α1HMZ and WTα1. Right, WTα7 (n = 4) and α7HMZ (n = 3) mice. \**P*\<0.05 versus WTα7. Results from one experiment per genotype are shown: a second independent experiment for α7HMZ yielded similar results (not shown). (**F**) Left, RELMβ mRNA expression in the distal colon of untreated α1HMZ, α7HMZ and their WT controls from microarrays in (**A**,**B**), represented as an average of the three *Retnlb* probes. *P*\<0.008 versus WTα7. Right, RELMβ protein level quantified by ELISA in the mid colon homogenate of untreated WTα7 (n = 5) and α7HMZ (n = 3) mice. Shown are means of technical triplicates. The following supplementary figure and source data are available for [Figure 5](#fig5){ref-type="fig"}:**DOI:** [http://dx.doi.org/10.7554/eLife.10903.010](10.7554/eLife.10903.010)10.7554/eLife.10903.011Figure 5---source data 1.Transcriptomic analysis of HNF4α isoform-specific mice.(**A**) Top 100 genes DOWN in distal colon of α1HMZ male mice compared to WT controls. (**B**) Top 100 genes UP in distal colon of α1HMZ male mice compared to WT controls. (**C**) Top 100 genes DOWN in distal colon of α7HMZ male mice compared to WT controls. (**D**) Top 100 genes UP in distal colon of α7HMZ male mice compared to WT controls. (**E**) Up-regulated genes involved in wound healing and immune function enriched in α1HMZ mice. (**F**) Up-regulated genes involved in cell cycle and DNA repair in α7HMZ mice. (**G**) Down-regulated genes involved in cell adhesion and ion transport in α7HMZ mice.**DOI:** [http://dx.doi.org/10.7554/eLife.10903.011](10.7554/eLife.10903.011)10.7554/eLife.10903.012Figure 5---source data 2.Proteomic analysis of HNF4α isoform-specific mice.(**A**) List of proteins that interact with HNF4α in α1HMZ and α7HMZ colons from RIME analysis meeting the criteria described in [Figure 5C](#fig5){ref-type="fig"}. (**B**) Select proteins that interact with HNF4α in α1HMZ and α7HMZ colons from RIME analysis used to prepare the graph in [Figure 5C](#fig5){ref-type="fig"}. (**C**) All peptides that interact with HNF4α in both α7HMZ and α1HMZ colons from RIME analysis in which there are at least 2 positives for each genotype. (**D**) All peptides that interact with HNF4α preferentially in α7HMZ colons in which there are 2 or more positives for α7HMZ compared to α1HMZ. (**E**) All peptides that interact with HNF4α preferentially in α1HMZ colons in which there are 2 or more positives for α1HMZ compared to α7HMZ. [Figure 5C](#fig5){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.10903.012](10.7554/eLife.10903.012)10.7554/eLife.10903.013Figure 5---figure supplement 1.Transcriptomic and BrdU analysis of HNF4α isoform-specific mice.(**A**) Total number of genes up- or down-regulated (non log fold change) in α1HMZ and α7HMZ untreated young adult male mice compared to their respective WT controls as determined by Affymetrix Exon arrays. (**B**) Position of BrdU+ cells in the distal colon of WTα7 and α7HMZ mice at 2 hr and 48--50 hr after injection. Left, distance in microns. Right, distance as percent of crypt length from the crypt bottom. \**P*\<0.02 for α7HMZ (n=4 mice) versus WTα7 (n=3 mice) at 48 hr. Data pooled from two independent experiments: 5--37 crypts counted per mouse. (**C**) Distance migrated in microns by Brdu+ cells between 2 hr and 48 hr from mice treated in (**B**). (**D**) As in (**B**) but for WTα1 (n=4) and α1HMZ (n=4) mice. \**P*\<0.005 between genotypes at 48--50 hr. Data are from one experiment. (**E**) As in (**C**) but for WTα1 and α1HMZ mice. (**F**) Total number of BrdU+ cells per crypt (5--38 crypts counted per mouse) in the distal colon of WTα7 and α7HMZ mice at 3 hr (n=7 per genotype) and 25 hr (n=3--4 per genotype) after BrdU injection.**DOI:** [http://dx.doi.org/10.7554/eLife.10903.013](10.7554/eLife.10903.013)

The DNA binding domains of P1- and P2-HNF4α are 100% identical and the isoforms have similar in vitro DNA binding specificity and chromatin immunoprecipitation (ChIP)-seq profiles in human colon cancer cells ([@bib71]). Therefore, to elucidate the mechanism responsible for differential gene expression in mouse colon, we performed RIME (Rapid Immunoprecipitation Mass spectrometry of Endogenous proteins) on HNF4α in the colons of α1HMZ and α7HMZ mice ([Figure 5C](#fig5){ref-type="fig"}). The isoforms share 76 interacting proteins, including previously reported HNF4γ ([@bib16]), a well known co-regulator for nuclear receptors (NRIP1, RIP140) and DPF2, a BRG1-associated factor (BAF45). However, there were more proteins uniquely binding HNF4α in α7HMZ and α1HMZ colons \-- 138 and 99, respectively ([Figure 5C](#fig5){ref-type="fig"} top and [Figure 5C---source data 2A--E](#SD2-data){ref-type="supplementary-material"}). Src tyrosine kinase, for example, bound uniquely in α1HMZ colons, consistent with our previous report that Src preferentially phosphorylates and interacts with HNF4α1 in cell-based and in vitro systems ([@bib15]) and validating RIME for identification of differential interacting proteins in vivo. In contrast, CUL4A, a core component of a cullin-based E3 ubiquitin ligase complex and overexpressed in cancer ([@bib44]), and PCM1, a centrosome binding protein translocated to the JAK2 locus in certain leukemias ([@bib60]), both bound uniquely in α7HMZ colons. Both CUL4A and PCM1 are required for efficient cell proliferation, genome stability and/or proper centrosome function ([@bib26]; [@bib28]), consistent with the upregulation of genes involved in cell cycle and DNA repair in α7HMZ colons ([Figure 5B](#fig5){ref-type="fig"}), and accelerated tumorigenesis in α7HMZ mice ([Figure 3E](#fig3){ref-type="fig"}).

Cross-referencing the interacting proteins to those in the literature associated with colon cancer and inflammatory bowel disease (IBD) revealed several additional relevant proteins for each genotype, the vast majority of which (62.9%) are known transcription regulators, protein kinases or phosphatases and associated proteins ([Figure 5C](#fig5){ref-type="fig"}). For example, NDRG2, a kinase downstream of the mTOR/SGK pathway and a tumor suppressor that mediates apoptosis ([@bib20]), and EMD, a nuclear membrane protein phosphorylated by Src ([@bib70]), both preferentially bind HNF4α1 and have been negatively associated with colon cancer. Likewise, HNF4α1 was preferentially bound by catalytic subunits of AMPK (PRKAA1/2) and is known to be phosphorylated by AMPK, which decreases its protein stability ([@bib40]). However, AMPK suppresses cell proliferation via inhibition of mTOR and activation of p53 pathways ([@bib52]) and low levels of AMPK activity are correlated with poor survival in metastatic colon cancer patients ([@bib77]), indicating that additional studies are required to elucidate the impact of AMPK signaling on HNF4α in colitis and colon cancer. In contrast, protein kinase C beta 2 (PRKCB) preferentially interacts with HNF4α7 and is known to be both necessary and sufficient to confer susceptibility to AOM-induced colon carcinogenesis in the colonic epithelium ([@bib45]). All told, there were hundreds of proteins that preferentially interacted with the HNF4α isoforms, including many signaling molecules as well as RNA binding proteins and transcription factors, providing multiple potential mechanisms for differential gene expression.

Differential effects on cell migration and chloride secretion in HNF4α isoform-specific mice {#s2-6}
--------------------------------------------------------------------------------------------

While the isoform-specific mice did not exhibit any overt morphological abnormalities in their intestines under normal conditions, the gene expression analysis (and AOM/DSS and DSS colitis results) suggested potential functional differences. Since there was a decrease in cell motility genes in α7HMZ mice, we examined migration of BrdU-labeled cells up the crypt and found that 48 hr after injection the average position of the BrdU-labeled cells (both in absolute terms and relative to the bottom of the crypt) was lower in α7HMZ mice compared to WT: this resulted in a statistically significant decreased migration of the BrdU+ cells during the 45 hr period ([Figure 5D](#fig5){ref-type="fig"} and [Figure 5---figure supplement 1B,C](#fig5s1){ref-type="fig"}). Conversely, the position of the BrdU+ cells, and hence migration, was significantly higher in α1HMZ mice ([Figure 5D](#fig5){ref-type="fig"} and [Figure 5---figure supplement 1D,E](#fig5s1){ref-type="fig"}). Despite these differences, there was a similar number of total BrdU+ cells in WT and α7HMZ mice ([Figure 5---figure supplement 1F](#fig5s1){ref-type="fig"}).

Since the ion transport genes were also decreased in α7HMZ, we examined electrogenic chloride secretion in isolated colonic mucosa. The distal colon of WT and α7HMZ mice exhibited a similar transmucosal electrical resistance and basal Isc (data not shown). However, the α7HMZ distal colon was refractory to stimulation with calcium-dependent (carbachol) and cAMP-dependent chloride secretagogues (forskolin), while the α1HMZ distal colon showed a markedly increased Isc response to forskolin ([Figure 5E](#fig5){ref-type="fig"}). Since impaired chloride secretion is observed in colitis ([@bib38]), this differential response to forskolin as well as cell migration could explain, at least in part, the differential sensitivity of the α1HMZ and α7HMZ mice to DSS.

Elevated RELMβ expression in α7HMZ mice plays a role in DSS sensitivity {#s2-7}
-----------------------------------------------------------------------

During experimental colitis the cytokine RELMβ is known to activate the innate immune system in response to loss of epithelial barrier function and increased exposure to gut microbiota: hence, mice lacking the *Retnlb* gene are known to be resistant to experimental colitis ([@bib39]; [@bib49]). Interestingly, one of the genes most significantly upregulated in the untreated α7HMZ colon was *Retnlb* (5.3-fold increase versus WT controls); RELMβ protein levels were also increased ([Figure 5F](#fig5){ref-type="fig"}). In contrast, there was no significant difference in RELMβ gene expression between α1HMZ mice and their WT littermates ([Figure 5F](#fig5){ref-type="fig"} left).

To determine whether RELMβ plays a causal role in the susceptibility of α7HMZ mice to colitis, we crossed α7HMZ mice with a RELMβ knock out (*Retnlb^-/-^*) to generate RbKO/α7HMZ mice ([Figure 6---figure supplement 1A](#fig6s1){ref-type="fig"}). We confirmed that RELMβ expression is lost in these mice, that HNF4α protein levels are unchanged by the RELMβ knock out and that the α7HMZ allele has the same effect in the \'Rb line\' (designated C57BL/6N+J, see Materials and methods for details) in terms of body weight loss and increased RELMβ expression after DSS treatment ([Figure 6A](#fig6){ref-type="fig"} and [Figure 6---figure supplement 1B--D](#fig6s1){ref-type="fig"}).10.7554/eLife.10903.014Figure 6.RELMβ knockout decreases susceptibility of α7HMZ mice to colitis.(**A**) RELMβ protein level quantified by ELISA in the midcolon homogenate of mice with the indicated genotype treated with 2.5% DSS for 6 days. Genotypes are indicated as *Retnlb/Hnf4a*. N = 3--5 mice per genotype as indicated by each dot. (**B**) Histological scores of colitis in WT/WT (n = 6), WT/α7HMZ (n = 9) and Rb KO/ α7HMZ (n = 11) male mice treated with 2.5% DSS for 5 days followed by 3 days of recovery. Multiple sections per mouse were scored. (**C**) Percent change in body weight during and following DSS treatment (2.5% for 6 days). Day 0 is the start of treatment. Left, graph over time from one experiment. N = 3--5 mice per genotype. ^\#^ Indicates *P\<*0.05 on day 10 and 11 between WT/WT and α7HMZ/WT; \* indicates *P\<*0.01 on day 10 and 11 between α7HMZ/WT and α7HMZ/Rb KO. Right, meta-analysis of percent weight loss at 3 days of recovery after 6 days of treatment with 2.5% DSS from nine independent experiments. N = 12--47 mice per genotype. The WT/α7HMZ data include both the α7HMZ C57BL/6N parent as well as the α7HMZ C57BL/6N+J generated from the *Retnlb*-/- cross. See [Figure 6---figure supplement 1](#fig6s1){ref-type="fig"} for a comparison of the two α7HMZ lines. (Data from one experiment in which all mice, including the WT/WT controls, had lower than normal body weight loss were excluded from the analysis.) (**D**) Colon length from mice treated with 2.5% DSS for 6 days followed by different recovery periods. N = 3--14 mice per genotype per treatment. \**P*\<0.05 versus WT/WT at different time points. ^\#^*P*\<0.01 or ^\#\#^*P*\<0.002 versus RbKO/α7HMZ at different time points. Data are pooled from 12 independent experiments. (**E**) Kaplan-Meier survival curve of WT/α7HMZ (n = 4) and KO/α7HMZ (n = 9) mice after 6 days 2.5% DSS in one experiment. Meta-analysis of several independent experiments also showed that out of a total of 24 KO/α7HMZ mice allowed to go past 3 days of recovery, only one mouse died (3.6% mortality). In contrast, 13 out of 29 WT/α7HMZ mice (44.8%) either died or had to be sacrificed due to severe distress. Data for WT/α7HMZ mice in both the C57BL/6N and C57BL/6N+J lines were combined: no difference in mortality was noted between the lines. (**F**) WT, α7HMZ and α1HMZ mice (all in C57BL/6N background, n = 3--63-6 per genotype per treatment) were treated with 2.5% DSS for 6 days alone or followed by 3 days of recovery. Left, RELMβ protein quantified by ELISA in the midcolon homogenate: shown are means of technical triplicates from one experiment. Right, colon length. RELMβ ELISA: \**P*\<0.03 versus WT; ^\#^*P*\<0.01 versus α7HMZ. Colon length: \**P*\<0.01 versus WT; ^\#^*P*\<0.0002 versus α7HMZ. The following figure supplement is available for [Figure 6:](#fig6){ref-type="fig"}:**DOI:** [http://dx.doi.org/10.7554/eLife.10903.014](10.7554/eLife.10903.014)10.7554/eLife.10903.015Figure 6---figure supplement 1.Verification of RELMβKO/α7HMZ mice.(**A**) Verification of genotype of RELMβ KO mice crossed into α7HMZ mice. Shown is a representative DNA agarose gel of PCR products generated with primers for the *Retnlb* and *Hnf4a* loci for 2 mice per genotype out of hundreds analyzed. Genotypes are written as *Retnlb/Hnf4a* loci. (**B**) IB of distal colon WCE using the HNF4α P1/P2 antibody showing roughly equivalent amounts of HNF4α protein in WT/WT and RbKO/α7HMZ mice. Extracts from one mouse are loaded per lane. (**C**) Percent change in body weight of α7HMZ mice from the two different lines \-- the parental α7HMZ line in C57BL/6N and the progeny from the cross with the RELMβ KO (C57BL/6N+J) \-- after 6 days of 2.5% DSS followed by 3 days of recovery from 4 (C57BL/6N) to 6 (C57BL/6N+J) independent experiments. N=15-26 mice per genetic background. One experiment was excluded in which the WT/WT mice serving as controls lost less than the usual amount of body weight, suggesting insufficient DSS treatment. (**D**) Representative IF from one of two mice stained per genotype for RELMβ in the distal colon of the indicated genotypes treated for 6 days with 2.5% DSS followed by 3 days recovery. Red, RELMβ. Blue, DAPI. (**E**) Percent change in body weight during and following DSS treatment (2.5% for 6 days). Day 0 is the start of treatment. Both α1HMZ (n=13 up to Day 6; n=8 up to Day 9) and α7HMZ (n=9 up to Day 6; n=4 up to Day 9) are in the C57BL/6N background. Data are pooled from two independent experiments except that α7HMZ Days 7--9 is from one experiment. \**P*\<0.05, \*\**P*\<0.005, \*\*\**P*\<0.0005.**DOI:** [http://dx.doi.org/10.7554/eLife.10903.015](10.7554/eLife.10903.015)

Interestingly, while the histological score of the RbKO/α7HMZ mice was somewhat improved compared to WT/α7HMZ at three days of recovery, the difference was not significant (*P*=0.13) ([Figure 6B](#fig6){ref-type="fig"}). In contrast, the weight loss of the RbKO/α7HMZ mice was completely restored to WT/WT levels ([Figure 6C](#fig6){ref-type="fig"}), as was the colon length ([Figure 6D](#fig6){ref-type="fig"}) and overall survival ([Figure 6E](#fig6){ref-type="fig"}). Notably, the RELMβ protein levels in the α1HMZ mice were significantly reduced at three days of recovery (although elevated right at the end of the DSS treatment) and inversely correlated with colon length ([Figure 6F](#fig6){ref-type="fig"}). These results suggest that elevated RELMβ expression in untreated and DSS-treated α7HMZ mice and decreased expression during recovery in α1HMZ mice might contribute to their increased and decreased susceptibility to DSS-induced colitis, respectively. Interestingly, body weight loss is attenuated in α1HMZ during DSS treatment, however this protective effect is lost during recovery ([Figure 6---figure supplement 1E](#fig6s1){ref-type="fig"}). All together our results suggest that both P1- and P2-HNF4α are critical for full recovery following DSS treatment.

Direct and indirect mechanisms regulate RELMβ expression in α7HMZ mice {#s2-8}
----------------------------------------------------------------------

To address the mechanism responsible for increased RELMβ expression in α7HMZ mice we performed ChIP in CaCo2 cells, which express predominantly P2-HNF4α ([@bib15]). We used the Support Vector Machine (SVM) learning tool in the HNF4 Binding Site Scanner to predict three potential HNF4α binding sites within 1.5 kb of the transcription start site (+1) of human *RETNLB* ([Figure 7A](#fig7){ref-type="fig"}, left and [Figure 7---figure supplement 1A-B](#fig7s1){ref-type="fig"}), two of which are in the vicinity of NFκB and CDX2 binding sites ([@bib74]; [@bib36]). We found that endogenous HNF4α binds the two regions that encompass the SVM sites (Region 1 and 2) ([Figure 7A](#fig7){ref-type="fig"}, right). The mouse *Retnlb* promoter also contains predicted HNF4α binding sites close to +1, one of which is highly conserved in human ([Figure 7---figure supplement 1B-C](#fig7s1){ref-type="fig"}, indicating that RELMβ expression may be directly regulated by P2-HNF4α in both mouse and human. Luciferase assays in LS174T goblet-like cells with RELMβ reporter constructs containing HNF4α binding sites in ChIP region 2 ([Figure 7---figure supplement 1D](#fig7s1){ref-type="fig"}) confirmed that P2-HNF4α activates the RELMβ promoter significantly more than P1-HNF4α ([Figure 7B](#fig7){ref-type="fig"}). siRNA knockdown of endogenous P1- and P2-HNF4α in LS174T cells also showed a greater effect of loss of endogenous P2-HNF4α on RELMβ expression than P1-HNF4α ([Figure 7---figure supplement 1E](#fig7s1){ref-type="fig"}). In contrast, on a known HNF4α-responsive promoter, ApoB, P1-HNF4α activates better than P2-HNF4α ([Figure 7---figure supplement 1F](#fig7s1){ref-type="fig"}).10.7554/eLife.10903.016Figure 7.Direct and indirect mechanisms of regulation of RELMβ expression by HNF4α isoforms: impact on DSS sensitivity and recovery.(**A**) P2-HNF4α binds the promoter of the *RETNLB* gene in colonic epithelial cells. Left, schematic of the human *RETNLB* promoter showing predicted SVM binding sites for HNF4α, as well as sites for NFκB, KLF4, STAT6 and CDX2 ([@bib36]). Right, ChIP results for endogenous HNF4α in Caco2 cells at RELMβ Region 1 and Region 2, as well as an *HMOX1* control. In, input (1/10 dilution); Ig, IgG; H4, anti-HNF4α. (**B**) Left, uciferase activity of pGL2.basic and RELMβ reporter constructs in LS174T cells cotransfected with vector (pcDNA3.1), human HNF4α2 or HNF4α8. Shown is the RLU normalized to protein concentration. Data are represented as mean of triplicates + *SD* of one independent experiment. \**P*\<0.05, \*\**P*\<0.005 between vector control and HNF4α2 or HNF4α8. ^\$^*P*\<0.05, ^\$\$^*P*\<0.005 HNF4α2 versus HNF4α8. Right, IB of extracts from LS174T cell line cotransfected with -870.hRELMβ reporter and HNF4α isoforms. (**C**) Gut permeability measured by appearance of FITC dextran (4 kDa) in serum of WT, α7HMZ and α1HMZ mice either untreated, treated with 2.5% DSS for 6 days alone or followed by 3 days of recovery. (n = 7--10 for all groups except α7HMZ 6d DSS + 3d recovery where n = 4). *P*-values were determined by Student's T-test. (**D**) List of genes related to barrier function altered in the distal colon of α7HMZ and α1HMZ mice compared to their WT controls. Shown is nonlog fold change from the microarray experiment in [Figure 5](#fig5){ref-type="fig"}. (**E**) Summary of various phenotypes of HNFα isoform-specific mice (α7HMZ and α1HMZ) relative to WT mice in untreated, DSS and AOM+DSS treated animals as indicated. n.d., not done. =, no change. (**F**) Distribution of HNF4α isoforms in colonic crypts and their effect on crypt structure in DSS-induced colitis. See text for details. The following figure supplement is available for [Figure 7](#fig7){ref-type="fig"}:**DOI:** [http://dx.doi.org/10.7554/eLife.10903.016](10.7554/eLife.10903.016)10.7554/eLife.10903.017Figure 7---figure supplement 1.Predicted HNF4α binding sites in the human and mouse RELMβ gene and RELMβ reporter assays.(**A**--**C**). Screenshots of UCSC Genome Browser shows putative HNF4α binding sites in human (**AB**) and mouse (**C**) RELMβ genes as well as the fragments amplified by the primers for Region 1 (**A**) and Region 2 (**B**). The SVM score from HNF4 Binding Site Scanner is given for the predicted sites in the RELMβ gene as well as the canonical HNF4α motif, AGGTCAaAGGTCA (**A**). Sites with scores above 1.0 are potential binders; sites with scores \>1.5 are predicted to be excellent binders. (**D**) Schematic of human RELMβ luciferase constructs used in (**E**) and Figure 7B with transcription factor binding sites and Region 2 bound by HNF4α in ChIP indicated. (**E**) Left, luciferase activity of pGL2.basic and RELMβ reporter constructs in LS174T cells transfected with siControl, siP1-HNF4α or siP2-HNF4α. Shown is the RLU normalized to β-gal activity. Data are mean of triplicates + SD of one independent experiment. \*\**P*\<0.005 between siControl and siP1-HNF4α or siP2-HNF4α. ^\$\$^*P*\<0.005 siP1-HNF4α versus siP2-HNF4α. Right, IB of WCE from LS174T cells transfected with the indicated siRNAs performed in parallel to the luciferase experiment. (**F**) Left, luciferase activity of ApoB (-85--47.E4) promoter construct co-transfected with HNF4α2 or HNF4α8 expression vector (500 ng) in COS-7 cells. Bar graphs represent mean ± SD of triplicate samples from one independent experiment. \*HNF4α2/8 vector compared to empty vector, ^\$^HNF4α2 vector compared to HNF4α8 vector, *P*\<0.05. Right, IB analysis of HNF4α protein level in COS-7 cells. COS-7 cells do not express endogenous HNF4α protein.**DOI:** [http://dx.doi.org/10.7554/eLife.10903.017](10.7554/eLife.10903.017)

Both P1 and P2-HNF4α are decreased after six days of DSS treatment in WT mice when RELMβ expression is increased ([Figures 2A](#fig2){ref-type="fig"} and [6F](#fig6){ref-type="fig"}), suggesting that additional mechanisms are at play in the upregulation of the *Retnlb* gene. Therefore, since RELMβ expression is known to be activated by decreased epithelial barrier function ([@bib49]), we conducted in vivo epithelial permeability assays using Fluorescein isothiocyanate--dextran 4 kDa (FITC-dextran) and found that α7HMZ mice have moderately decreased barrier function as shown by increased FITC-dextran in the serum of both untreated and DSS-treated mice ([Figure 7C](#fig7){ref-type="fig"}). Furthermore, we found decreased FITC-dextran in α1HMZ mice compared to α7HMZ at 3 days of recovery ([Figure 7C](#fig7){ref-type="fig"}), suggesting improved barrier function, consistent with the lower levels of RELMβ and longer colon length in α1HMZ mice ([Figure 6F](#fig6){ref-type="fig"}). Barrier function and colon length are both indicators of colon health.

Analysis of the expression profiling data in the untreated mice revealed dysregulation of several genes related to barrier function ([Figure 7D](#fig7){ref-type="fig"} and [Figure 5---source data 1G](#SD1-data){ref-type="supplementary-material"}). For example, *Il4i1* and *Il13ra2,* known signaling pathways critical for RELMβ expression ([@bib3]), are both increased in α7HMZ mice. There was also a concerted decrease in the expression of genes involved in cell adhesion and paracellular permeability in α7HMZ (*Cdh1, Cldn15, Cldn16* and *Sh3bp1*), which would contribute to decreased barrier function and hence increased DSS sensitivity and RELMβ expression in α7HMZ.

Discussion {#s3}
==========

The majority of mammalian genes have alternative promoters, which often result in different transcript variants, but relatively little is known about the physiological relevance of those transcript variants ([@bib21]; [@bib75]). Here, we examined the HNF4α gene, which has two highly conserved promoters (P1 and P2) that give rise to proteins with different N-termini (P1-HNF4α and P2-HNF4α). Even though both promoters are expressed in adult intestines ([@bib68]; [@bib53]; [@bib10]) and HNF4α has been implicated in human colon cancer ([@bib15]; [@bib68]; [@bib57]; [@bib11]; [@bib76]) and colitis ([@bib1]; [@bib5]; [@bib27]), the distribution and function of the different HNF4α isoforms in the colon have not been investigated until now (results summarized in [Figure 7E](#fig7){ref-type="fig"}). We show that in untreated WT adult mice P1-HNF4α protein is expressed in the differentiated compartment and the surface of the colonic epithelium whereas P2-HNF4α expression is restricted to the proliferative and differentiated compartments ([Figure 7F](#fig7){ref-type="fig"}). Transgenic mice expressing just a single isoform of HNF4α developed morphologically normal intestines, but hundreds of genes in the colon were differentially expressed compared to WT mice, many of which are consistent with altered barrier function and localization of the isoforms: mice expressing only P1-HNF4α (α1HMZ) had an upregulation of genes involved in differentiation, while mice expressing only P2-HNF4α (α7HMZ) had higher levels of DNA repair and cell cycle genes. Furthermore, we found that HNF4α isoforms interact in vivo with unique sets of proteins, especially those involved in signal transduction, which could contribute to differential gene expression patterns and thereby result in different susceptibilities to colitis and colitis-associated colon cancer in the isoform-specific mice. Finally, we show that *Retnlb*, which encodes the cytokine RELMβ, a key player in DSS-induced colitis, is a downstream target of P2-HNF4α.

Role of HNF4α isoforms in colon cancer {#s3-1}
--------------------------------------

In a mouse model of CAC, α1HMZ mice exhibited decreased tumor load, suggesting that expression of HNF4α1 from the P2 promoter in the proliferative compartment may protect against tumorigenesis, consistent with studies showing a loss of P1-HNF4α in human colon cancer ([@bib15]; [@bib68]; [@bib57]), a tumor suppressive role for P1-HNF4α in mouse liver ([@bib34]; [@bib73]) and our recent colon cancer xenograft studies showing that ectopic expression of P1-HNF4α reduces tumor growth ([@bib71]). In contrast, α7HMZ mice showed an initial increase in tumorigenesis, which could reflect the absence of P1-HNF4α. Since there was no increase in the number of Ki67- or BrdU-positive cells in α7HMZ colons, no visible tumors after a chronic colitis regimen (three cycles of DSS treatment) (data not shown) nor acceleration of tumor growth in the presence of ectopic expression of P2-HNF4α in the xenograft model ([@bib71]), there is no indication that P2-HNF4α actively promotes proliferation. Rather, P2-HNF4α appears to be merely permissive of cell proliferation, consistent with its expression in the proliferative compartment and its retention in human colon cancer ([@bib15]; [@bib68]).. Interestingly, HNF4α has been shown to act as an oncogene in gastric cancer and only P2-HNF4α is expressed in the stomach ([@bib14]; [@bib19]).

Role of HNF4α isoforms in DSS-induced colitis {#s3-2}
---------------------------------------------

An additional and/or alternative explanation for the differences in CAC-induced tumors in the isoform-specific mice could be their remarkable differences in DSS sensitivity, which in turn could be due to opposing chloride secretory responses and epithelial migration ([Figure 7E](#fig7){ref-type="fig"}). Since the chloride secretory pathway is required for maintaining proper luminal hydration, which helps protect the epithelium from physical damage ([@bib6]), this suggests that the isoform-specific mice have different barrier functions, which we confirmed with FITC-dextran assays. Decreased expression of cell adhesion genes in α7HMZ colons \-- such as E-cadherin (*Cdh1*), an established HNF4α target ([@bib7]; [@bib24]) critical for both migration of cells along crypt-villi axis and epithelial barrier function ([@bib31]; [@bib63]) \-- would contribute to decreased barrier function. In contrast, downstream effectors of IL-18 signaling (*Il18r1* and *Il18rap)*, which are implicated in intestinal epithelial barrier function ([@bib55]), were increased in α7HMZ mice, while *Il18bp*, a decoy receptor for IL-18 which attenuates signaling, is decreased. All told, there are several key cell adhesion and cytokine signaling genes that are dysregulated in α7HMZ colons that could contribute to decreased barrier function and subsequently a pro-inflammatory state ([@bib39]; [@bib49]), which could in turn contribute to the enhanced colitis and tumorigenesis observed in α7HMZ mice. One such cytokine is RELMβ, which we show is a direct target of HNF4α and preferentially activated by P2-HNF4α.

DSS also causes epithelial injury and a need for rapid proliferation, expansion, migration and differentiation of intestinal epithelial cells to promote wound healing and regeneration ([@bib65]). Hence, the inability of α7HMZ mice to effectively recover from DSS could be attributed to defective migration, chloride secretion (ion transport) and/or differentiation ([Figure 7F](#fig7){ref-type="fig"}). BrdU-labeled cells exhibited greater migration in α1HMZ and lower migration in α7HMZ mice: α7HMZ mice also had reduced expression of genes involved in cell motility. *Cldn15* is downregulated in α7HMZ and upregulated in α1HMZ colons and a known target of HNF4α ([@bib17]). *Cldn15* dysregulation could explain the decrease in secretory capacity in α7HMZ mice and hence their inability to recover after DSS as a basal level of secretion is important for proper gut formation ([@bib2]; [@bib67]). *Cdx2*, another established target of HNF4α ([@bib62]) and a major player in intestinal differentiation ([@bib66]; [@bib46]), has a similar expression profile. Finally, the involvement of these processes in recovery from DSS could explain why the crypt structure in the α7HMZ mice is not completely ameliorated by the RELMβ knockout even though body weight and colon length loss and lethality are: it has been noted previously that RELMβ expression per se does not alter colonic epithelial proliferation [@bib49] and its role in affecting the barrier function is still debated ([@bib39]; [@bib49]).

In summary, the results presented here indicate that while P1- and P2-HNF4α isoforms can substitute for each other during normal development and homeostasis, under conditions of stress they play notably different roles. Those roles seem to be driven by unique interacting partners leading to differential expression of target genes. The results also show that any factor that disrupts the balance between the HNF4α isoforms in the colon could have serious functional consequences. Those factors include Src tyrosine kinase ([@bib15]), as well as any one of a number of other signaling molecules that interact preferentially with the isoforms. Future studies will be required to elucidate all the underlying mechanisms but it is anticipated that several will be important in diagnosing and treating gastrointestinal diseases involving HNF4α.

Materials and methods {#s4}
=====================

Animal use and care {#s4-1}
-------------------

Care and treatment of animals were in strict accordance with guidelines from the University of California Riverside Institutional Animal Care and Use Committee (Protocol number A200140014). Mice were maintained in isolator cages under 12 hr light/dark cycles at \~21°C on bedding (Andersons bed OCOB Lab 1/8 1.25CF) from Newco (Rancho Cucamonga, CA) and either fed a standard lab chow (LabDiet, \#5001, St. Louis, MO) and maintained in an open access vivarium or fed an irradiated chow (LabDiet, \#5053) and housed in a specific pathogen-free (SPF) vivarium (α7HMZ and *Retnlb*^-/-^ matings). All experiments were performed in an open access vivarium except those in Figure 4CEF where the mice were born in an open-access vivarium and then moved to an SPF facility before treatment (due to a required institutional change). Subsequently, mice born in the SPF facility were brought to an open access facility at least two weeks prior to DSS treatment.

Transgenic mice on a mixed 129/Sv plus C57BL/6 background carrying exon 1A or exon 1D in both the P1 and P2 promoter (α1HMZ or α7HMZ, respectively) have been described previously ([@bib10]). Both lines were maintained as heterozygotes (HTZ); wildtype (WT) and homozygous (HMZ) were mated for a single generation to generate mice for experiments. Appropriate, age-matched WT controls for both the α1HMZ and α7HMZ lines were used (designated WTα1 and WTα7, respectively, [Figures 1](#fig1){ref-type="fig"}--[5](#fig5){ref-type="fig"}). The α7HMZ and α1HMZ mice were backcrossed to C57BL/6N for 10+ generations and used with C57BL/6N WT controls ([Figure 6](#fig6){ref-type="fig"}). The backcrossed α7HMZ mice were crossed with RELMβ knockout (*Retnlb*^-/-^) mice which were generated as previously described ([@bib39]) using VelociGene technology. The *Retnlb*^-/-^ mice were backcrossed 6+ generations in C57BL/6J to generate RbKO/α7HMZ mice in a C57BL/6N+J background. WT/α7HMZ mice from the RELMβ cross showed essentially identical susceptibility to DSS as the α7HMZ parent in the C57BL/6N background (as well as the original exon swap mice in the mixed background) ([Figure 6---figure supplement 1C](#fig6s1){ref-type="fig"} and data not shown). All experiments with RbKO/α7HMZ mice were compared to RbWT/α7HMZ from the RELMβ cross except for the meta analysis in [Figure 6C](#fig6){ref-type="fig"} which included data from the parental α7HMZ line in C57BL/6N. Mice of the same genotype were housed three to five per cage, randomly assigned to treatment groups at the beginning of the experiment and subjected to a single experimental regime in their cages. Mice were euthanized by CO~2~ asphyxiation and tissues harvested in the mid morning to mid afternoon.

DSS colitis {#s4-2}
-----------

Male mice (10 to 16 weeks old) were treated with 2.5% DSS (MW 36,000--50,000 Da, MP Biomedicals, \#160110, Santa Ana, CA) in water given ad libitum for four to six days and sacrificed immediately or allowed to recover up to 18 days with tap water. WT mice were treated in parallel in each experiment as controls for the DSS: the same lot number of DSS was used for a given group of experiments whenever possible to avoid lot-to-lot variation. Mice in severe distress (weighing 13 grams or less, or excessively hunched and lethargic) were euthanized prior to the termination of the experiment except in experiments measuring mortality. To avoid confounding effects due to unrelated illnesses, when an animal became unexpectedly ill, all mice in the cage were excluded from the analysis.

Colitis-associated and sporadic colon cancer {#s4-3}
--------------------------------------------

CAC was established as described ([@bib54]). Briefly, we intraperitoneally (i.p.) injected male mice (6 to 10 weeks old) with 10 mg/kg AOM (National Cancer Institute, Bethesda, MD) on Day 1 in the morning. On Day 2 mice were given 2.5% DSS in water for four to seven days, followed by 16 days of untreated water; the cycle was repeated one or two additional times. Mice were sacrificed at day 46 to 95; tumor number counted by visual inspection and tumor size measured with digital calipers were determined in a blind fashion. Sporadic colon cancer was induced in male mice (6 to 8 weeks old) by i.p. injection of 10 mg/kg AOM once a week for six consecutive weeks. Mice were sacrificed 28 weeks after the first injection.

H&E staining and immunofluorescence {#s4-4}
-----------------------------------

Distal colons were fixed in 10% phosphate buffered formalin and stained with hematoxylin and eosin (H&E) or for immunofluorescence (IF) as described previously ([@bib68]; [@bib47]). For antigen retrieval, tissue sections were soaked in 1% SDS in phosphate buffered saline (PBS) and microwaved for 2 min for all antibodies except for P2-HNF4α which was autoclaved at 121°C for 20 min in 10 mM citrate buffer. Images were captured with a Zeiss 510 confocal microscope. Mouse monoclonal antibodies to P1/P2-driven HNF4α (\#PP-H1415-00), P1-driven HNF4α (\#PP-K9218-00) and P2-driven HNF4α (\#PP-H6939-00) were from R&D Systems (Minneapolis, MN). Antibodies to Ki67 were from Abcam (\#ab1667, Cambridge MA). Rabbit NKCC1 antibody (TEFS2) has been described previously ([@bib48]). Alexa fluor anti-mouse and anti-rabbit secondary antibodies and TO-PRO-3 nuclear stain (red) were from Life Technologies (Carlsbad, CA). For RELMβ IF staining, antigen retrieval was performed by immersion of slides in 95--100°C pre-heated sodium citrate buffer (10 mM). Following cooling to room temperature, slides were rinsed twice with PBS/0.1% Tween 20 for 5 min and then blocked with 5% normal donkey serum (Jackson Immuno Research Labs, Westgrove, PA) in StartingBlock (Thermo Scientific, Carlsbad, CA). Sections were stained with rabbit anti-RELMβ antibody (\#500-P215, Peprotech, Rocky Hill, NJ), followed by fluorochrome-conjugated anti-rabbit antibody (Abcam), and counterstaining with DAPI (Cell Signaling Technology, Danvers, MA).

Immunoblot {#s4-5}
----------

Whole cell extracts (WCE) were prepared from either snap-frozen or fresh tissue using ice-cold Triton lysis buffer by motorized (Wheaton, Millville, NJ) or manual homogenization. Triton lysis buffer was 20 mM Tris pH 7.5, 150 mM NaCl, 10% glycerol, 1% NP40, 1% Triton-X-100, 1 mM EDTA, 2 mM EGTA plus inhibitors (1 μg/ml of aprotonin, leupeptin and pepstatin, 1 mM of sodium orthovanadate, sodium fluoride and (PMSF), phosphatase inhibitor cocktail I & II (1:100), protease inhibitor cocktail (1:10 -- 1:100), Sigma-Aldrich, St. Louis, MO). Protein extracts (\~20--100 μg) were analyzed by 10% SDS-PAGE followed by transfer to Immobilon (EMD Millipore, Billerica, MA) before staining with antibodies or Coomassie for protein loading.

Histological scoring {#s4-6}
--------------------

Blinded histology scoring of H&E stained sections was performed according to three criteria. Crypt damage: 0 = intact crypts, 1--2 = loss of basal area, 3--4 = entire crypt loss with erosion, 5 = confluent erosion. Leukocyte inflammation: 0 = no inflammatory infiltrate, 1 = leukocyte infiltration in the lamina propria, 2 = leukocyte infiltration extending into the submucosa, 3 = transmural and confluent extension on inflammatory cells. Ulceration: 0 = no ulcers, 1--2 = presence of ulcers, 3 = confluent and extensive ulceration.

BrdU labeling {#s4-7}
-------------

Young adult male mice were injected i.p. with 75 mg/kg BrdU (BD Biosciences, \#550891, San Jose, CA) and sacrificed after 2 to 3 hr, 25 hr or 48--50 hr. Distal colons fixed in formalin were sectioned and immunostained with BrdU antibody as per manufacturer instruction (BD Biosciences, \#550803). Images were captured at 40X (Zeiss Axioplan, Jen Germany) and crypt dimensions were measured using SPOT Imaging software (Sterling Heights, MI).

Isolation of mouse colonic crypts {#s4-8}
---------------------------------

Distal colons from 19-week-old male WT mice from the mixed background (WTα7) were rinsed in PBS, placed in a 4% bleach solution for 20 min, washed three times in PBS and then incubated with 3 mM EDTA, 0.5 mM (DTT) in PBS for 90 min at 4°C followed by a PBS wash. Colonic crypts were isolated by vigorous shaking; they were fixed and immunostained as described ([@bib15]).

Ussing chamber assay {#s4-9}
--------------------

The short circuit current (I~sc~) and electrical resistance across the mucosal layer of mouse distal colon was measured using an Ussing chamber as described ([@bib4]). Electrogenic Cl^−^ secretion was recorded as the I~sc~ evoked by sequential addition of 100 µM carbachol and 20 µM forskolin (Sigma-Aldrich) to the serosal bath.

Expression profiling {#s4-10}
--------------------

Mouse Exon 1.0 ST Arrays (Affymetrix, Santa Clara, CA) were hybridized at the University of California Riverside Genomics Core using polyA+ RNA extracted from the distal colon of young adult male mice (12 to 16 weeks old) fed a standard lab chow ad libitum in an open access vivarium. RNA was pooled from two to three mice per genotype and applied to one array; a second array was processed in a similar fashion for a total of four to six mice assayed per genotype. Results from the two arrays were averaged. Isoform-specific mice were compared to their appropriate, age-matched WT controls. Data were analyzed using Robust Multi-array Average (RMA) background adjustment and quantile normalization on probe-level data sets with Bioconductor packages, Exonmap, and Affy software. To determine the differentially expressed transcripts only the probes with *P*\<0.05 (Student's *t*-test) and more than two-fold change were considered. Gene Ontology (GO) overrepresentation analysis was conducted using DAVID. Microarray data have been deposited in the Gene Expression Omnibus MIAME-compliant database (Accession number GSE47731) (<http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE47731>).

RELMβ ELISA {#s4-11}
-----------

Colon tissue (\~1 cm) was weighed and homogenized in 0.5 mL PBS, followed by ELISA with capture and detection biotinylated antibodies for anti-RELMβ (Cat \#500-P215Bt, Peprotech) according to the manufacturer's instructions. Samples were compared to a serial-fold dilution of recombinant mouse RELMβ protein (\#450-26B, Peprotech) and calculated as ng per gram tissue. All ELISAs were performed in technical triplicates.

Chromatin immunoprecipitation (ChIP) followed by PCR {#s4-12}
----------------------------------------------------

Human colonic epithelial cells Caco2 cells (ATCC HTB-37) were grown in DMEM (Dulbecco's modified Eagle's medium with 4.5 g/liter glucose, L-glutamine, and pyruvate) supplemented with 20% fetal bovine serum (FBS) (BenchMark; cat\#100--106) and 100 U/mL penicillin-streptomycin (1% P/S) at 37°C and 5% CO~2~. At \~95% confluency the cells were crosslinked with formaldehyde and subjected to ChIP analysis using the affinity purified anti-HNF4α antisera (α445), which recognizes the very C-terminus of both P1- and P2-HNF4α, as described previously ([@bib71]). The following primers in the *RETNLB* promoter were used in the PCR for 40 cycles: Region 1 forward 5'-CTCCTCCACCTCTTCCTCCT-3' and reverse 5'-CATCCTAATCCCCCTTCTCC-3' (301 bp); Region 2 forward 5'-CCTTTGCTCTGGATCTCTGC-3' and reverse 5'- ATGAGCCCCCAAAAGAACTC-3' (405 bp). Primers in the *HMOX1* promoter were used as a positive control, forward 5'-CCTCTCCACCCCACACTGGC-3' and reserve 5'-GCGCTGAGGACGCTCGAGAG-3' (179 bp). Primers were designed using the UCSC genome browser (<https://genome.ucsc.edu/>) and Primer3 (v.0.4.0) (<http://bioinfo.ut.ee/primer3-0.4.0/>[)]{.ul}. Predicted HNF4α binding sites (Support Vector Machine, SVM, algorithm) were identified using the HNF4α Binding Site Scanner (<http://nrmotif.ucr.edu/>) ([@bib8]).

Fluorescein isothiocyanate--dextran (FITC-dextran) assay {#s4-13}
--------------------------------------------------------

Intestinal epithelial permeability was assessed by measuring the appearance of FITC-dextran (FD-4, Sigma) in mouse serum as described previously ([@bib9]). Untreated or treated (2.5% DSS for six days or 2.5% DSS for six days, followed by days of recovery with tap water) WT, α7HMZ or α1HMZ mice were fasted overnight and then gavaged with FITC-dextran (60 mg/100 g body weight) 4 hr before harvesting. Blood was collected either from the inferior vena cava or by cardiac puncture and allowed to sit on ice for 30 min. Serum was collected after centrifuging the blood for 15 min at 2000 xg at 4°C. FITC-dextran measurements were performed in duplicate or triplicate by fluorometry at 490 nm. Data were analyzed using Prism 6 software (GraphPad Prism version 6 for Mac, GraphPad Software, La Jolla, CA); outliers were identified by the ROUT method and removed.

Plasmids and siRNA {#s4-14}
------------------

Human HNF4α2 (NM_000457) and HNF4α8 (NM_175914.3) constructs in pcDNA3.1 (+) vector were gifts from Dr. Christophe Rachez (Pasteur Institute, Paris, France) as described previously ([@bib15]). pGL2.basic, human RELMβ reporter constructs and LS174T cells were gifts from Dr. Gary Wu ([@bib74]).

ON-TARGET siRNA targeting P1- and P2-HNF4α were custom synthesized from Dharmacon. si P1-HNF4α: Sense, 5\'-U U G A G A A U G U G C A G G U G U U U U -3\'; Antisense 3\'-U U A A C U C U U A C A C G U C C A C A A -(5\'-P) 5\'. siP2-HNF4α: Sense, 5\'-G U G G A G A G U U C U U A C G A C A U U-3\'; Antisense, 3\'-U U C A C C U C U C A A G A A U G C U G U-(5\'-P) 5\'. ON-TARGETplus Non-targeting siRNA \#1 (D-001810-01-20) was used as siControl.

Luciferase assay {#s4-15}
----------------

LS174T cell lines were grown in DMEM supplemented with 10% FBS and penicillin-streptomycin (1% P/S) and maintained at 37°C and 5% CO~2~. For siRNA experiments, 8X10^6^ LS174T cells were plated in 60-mm plates and transfected 24 hr after plating with 100 nM siRNA using RNAi Max (Invitrogen) according to the manufacturer's protocol. Forty-eight hours after transfection, cells were split into a 24-well plate (8X10^6 ^cells per well), and 24 hr later transfected with Lipofectamine 3000 according to the manufacturer's protocol (Invitrogen) with CMV.βgal (50 ng) and pGL2.basic or human RELMβ reporter constructs (1 μg). For HNF4α transfections, 8X10^6 ^LS174T cells were plated in 24-well plates and 24 hr later transfected with human HNF4α2 or HNF4α8 (100 ng), CMV.βgal (50 ng) and pGL2.basic or human RELMβ reporter constructs (1 μg). Cells were harvested 24 hr after transfection using passive lysis buffer (Promega). Luciferase and β-gal activity were measured as described previously ([@bib15]).

RIME (Rapid Immunoprecipitation Mass spectrometry of Endogenous proteins) for mouse colon {#s4-16}
-----------------------------------------------------------------------------------------

RIME was carried out as previously described ([@bib51]), with the following modifications. Whole colon from α1HMZ and α7HMZ untreated male mice (n = 3 per genotype, \~16 weeks of age, backcrossed into C57/BL6N and maintained in an SPF vivarium) were fixed in 1.1% methanol-free formaldehyde (5 mL) \[in 1 x phosphate buffered saline (PBS plus 1 mM PMSF and DTT, 2 μg/mL leupeptin and aprotinin, and 1:200 protein phosphatase inhibitors I (2&3) (Sigma)\] for 10 min at RT; crosslinking was then stopped with 0.125 M glycine for 5 min at RT. Fixed colon was further processed into single cells at 4°C. Colon was lightly minced with a razor blade and disaggregated in PBS plus inhibitors (as above) by passing through a motorized homogenizer. The cells were then drained through a cell strainer and dounced using a hand-held homogenizer. Cells were swelled in 1.0 mL Hypotonic Buffer (10 mM HEPES-KOH pH 7.9, 10 mM KCl, 1.5 mM MgCl~2~) plus inhibitors for 10 min at 4°C and centrifuged to collect the nuclei. The pellet was washed with Nuclei Buffer (1% SDS, 50 mM Tris-Cl pH 8.0, 10 mM EDTA) plus inhibitors and D3 Buffer (0.1% SDS, 10 mM Tris-Cl, 1 mM EDTA). The pellet was resuspended in fresh 0.5 mL D3 Buffer plus inhibitors, transferred to a 1.0 mL AFA millitube with a plastic stirring rod and more D3 Buffer was added to fill the tube (total volume \~780 μL). Samples were sonicated for 9 min (4 min per 200 cycles/bursts, 5.0 duty force, and 140 peak power; one min delay) in a Covaris S220, Bioruptor and pre-cleared for 30 min in 10 μL of magnetic beads (Pierce Thermo Scientific, cat\#88802). Prior to use, magnetic beads were washed 3 x 1.0 mL in cold PBS. Samples were split in half and diluted 1:1 with Immunoprecipitation (IP) Dilution Buffer (0.01% SDS, 20 mM Tris-Cl pH8.0, 1.1% Triton X-100, 167 mM NaCl, 1.2 mM EDTA) and placed in non-stick tubes. Each half sample was incubated with 40 μL of magnetic beads that were pre-incubated with 21 μg of anti-HNF4α (α-445) ([@bib64]) or rabbit IgG in 0.05% Tween PBS at 4°C overnight. The following day, IPs were washed 3 x 1.0 mL with ice cold Radioimmunoprecipitation assay (RIPA) Buffer (15 mM Tris-Cl, 150 mM NaCl, 1% NP-40, 0.7% deoxycholate), washed 1 x 400 μL with DNaseI Buffer (40 mM Tris-Cl, 1 mM CaCl~2~, 10 mM NaCl, 6 mM MgCl~2~) and incubated in 100 μL DNaseI Buffer and 8 μL of DNaseI enzyme (4 μg/μL) for 20 min at 30°C. Additional washes were done (3 x 0.5 mL with RT RIPA Buffer and 2 x 1.0 mL with cold RIPA Buffer). IP'd material was washed twice with cold 50 mM NH~4~CO~3~. At the last wash (0.5 mL), samples were transferred to new tubes. Wash buffer was removed and IP beads subjected to mass spectrometry as follows:

Sample beads were washed with trypsin digestion buffer, digested with trypsin overnight and subjected to 2D-nanoLC/MS/MS analysis at the UCR Institute of Integrated Genome Biology Proteomics Core as described previously ([@bib22]). Briefly, a MudPIT approach employing a two-dimension nanoAcquity UPLC (Waters, Milford, MA) and an Orbitrap Fusion method (Thermo Scientific, San Jose, CA) was used to analyze all sample. Data were acquired using Orbitrap fusion method ([@bib37]) with acquisition time set from 1--70 min. For MS2 scanning only precursor ions with intensity of 50,000 or higher were selected and scanned from most intense to least intense precursor ions within 4 s. A 5-s exclusion window was applied to all abundant ions to avoid repetitive MS2 scanning on the same precursor ions using 10 ppm error tolerance. All raw MS data were processed and analyzed using Proteome Discoverer version 2.1 (Thermo Scientific, San Jose, CA). Only proteins with 1% FDR cut-off (q[\<]{.ul}0.01) were considered for subsequent analysis.

Proteins had to be present in at least two out of the three replicates with the HNF4α antibody and not in any IgG control in both α1HMZ and α7HMZ samples to be considered for the \'both\' category. To be considered in the \'α7HMZ only\' category, the protein had to appear either in two of three α7HMZ samples but in none of the three α1HMZ samples, or in three of the α7HMZ samples and only one of the α1HMZ samples. A similar strategy was used for the \'α1HMZ only\' proteins. Proteins were converted to gene symbols and cross-referenced with human and mouse genes associated with colon cancer, IBD, Crohn's disease and ulcerative colitis found in the literature ([@bib29]; [@bib42]) and a Pubmed-Gene search conducted in April 2016, followed by manual curation. Gene Ontology using Panther ([www.pantherdb.org](http://www.pantherdb.org)) as well as manual curation resulted in the TF, RNA binding and protein kinase and phosphatase categories in [Figure 5C](#fig5){ref-type="fig"} bottom. The Human Protein Atlas (<http://www.proteinatlas.org/>) was used to confirm expression in the colon and nucleus.

Statistical analyses {#s4-17}
--------------------

Sample sizes for DSS and AOM+DSS regimes were determined on the basis of mouse-to-mouse variation in body weight loss and tumor number/load (respectively) observed in pilot experiments. Each mouse was considered to be a biological replicate; technical replicates refer to multiple analyses of the same tissue from a given animal. All results are expressed as the mean ± s.e.m, of sample size *n*. Significance was tested by analysis of variance or Student\'s *t*-test. Probabilities less than 5% (*P*\<0.05) were considered to be significant. For RIME, a cut off of q\<0.01 (1% FDR) was used.
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Major datasets {#s7}
--------------

The following dataset was generated:

Karthikeyani Chellappa, Eugene Bolotin, Frances M Sladek,2013,Differential role of HNF4alpha isoforms in colitis and colitis-associated colon cancer,<http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE47731>,Publicly available at NCBI Gene Expression Omnibus (accession no: GSE47731)
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United States

In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your work entitled \"Opposing roles of nuclear receptor HNF4α isoforms in colitis and colitis-associated colon cancer\" for peer review at *eLife*. Your submission has been favorably evaluated by Kevin Struhl (Senior editor) and an additional expert reviewer.

The reviewers have discussed the reviews with one another and the Reviewing editor has drafted this decision to help you prepare a revised submission.

Both reviewers think that the paper is interesting and potentially appropriate for publication in *eLife*. However, though nicely demonstrated, the conclusion that the P1 form is tumor suppressing and the P2 form is oncogenic is insufficient for publication in *eLife*. What is missing is a mechanistic connection between the 2 isoforms and expression of RELMβ. Thus, publication in *eLife* requires making such a mechanistic connection, particularly showing that the P2 isoform, but not the P1 isoform, activates the RELMβ promoter through HNF4α sites. There are several possible options (reporter assays, ChIP, mutation of the site) that could be completed in the standard 2-month period (or slightly longer) since they are standard experiments. Ideally, it would be nice to show that P2-mediated regulation of RELMβ per se is critical in mice as mentioned by Reviewer 1, but this is likely to take too long and is not required. For your information, the full reviews are included below.

*Reviewer \#1:*

This paper presents useful data, but it belongs in a more specialized journal. There is already a considerable body of evidence indicating that the HNF4α isoforms are differentially regulated and have different functions. In particular, there is considerable evidence that the P1 form acts as a tumor suppressor. Also, over-expression of HNF4α is oncogenic despite the P1 form, suggesting that P2 acts as an oncogene. The authors nicely test this by generating mice that can only express either the P1 or P2 isoforms and assessing various phenotypes including gene expression profiles and colitis susceptibilities, the authors significantly improve the understanding of the distinct roles of these isoforms. To this non-expert, the experiments generally seem fine with clear results. However, the differences between the isoforms are phenomenological with limited mechanistic understanding, and their opposing roles in colitis and colitis-associated colon cancer are in accord with previous characterization as tumor suppressing and tumor promoting. As such, I think this paper will be of interest to specialists in HNF4α and colitis/colon cancer, but it is unclear what findings are of more general significance.

It is already known that loss of RELMβ causes resistance to colitis. The new finding here is this gene is up-regulated by the P2 form, which of course also stimulates colitis. So, the knock-out result is largely expected. Moreover, the conclusion that P2-mediated up-regulation of RELMβ is important is not really tested. The correct experiment would be to knock out HNF4 sites that are required for the up-regulation of RELMβ and show that this blocks colitis. Alternatively, some other manipulation that reduces RELMβ levels to the uninduced level. To put it differently, one has to show that the regulation of RELMβ is important, not just the gene itself which is already known. I realize this is a fair amount of work.

*Reviewer \#2:*

HNF4α expression in the gut has been linked to both colitis and colon cancer. Chellapa et al. describe strikingly differential effects of distinct isoforms of HNF4α in the gut. Expression of the P2 promoter isoform only results in increased sensitivity to DSS and increased tumorigenesis in an AOX/DSS model, while opposite results are observed with mice that express only the P1 isoforms. Within the context of nuclear receptor function, it is well known that there are multiple isoforms of many NRs, but they are generally not distinguished functionally. Thus, this represents a particularly clear example of delineation of distinct functions of different isoforms. This observation might be of more limited interest, but clear mechanistic information is provided by the demonstration that RELMβ is overexpressed in the DSS sensitive P2-specific mice, and that doubly mutant P2 specific/RELMβ knockout mice are resistant to the increased sensitivity to DSS.

One question raised by these results is whether the effects of the different isoforms on RELMβ expression are direct or indirect, and particularly whether the distinct isoforms have distinct direct effects on RELMβ expression. This study would be further strengthened if relatively straightforward RELMβ promoter cotransfections showed such effects, or if other strategies could document differential promoter occupancy.

\[Editors' note: what now follows is the decision letter after the authors submitted for further consideration. The paper was rejected in the second round of review, but then accepted after the authors appealed against the decision.\]

Thank you for submitting your work entitled \"Opposing roles of nuclear receptor HNF4α isoforms in colitis and colitis-associated colon cancer\" for consideration by *eLife*. Your article has been reviewed by one of the original peer reviewers, and the evaluation has been overseen by Kevin Struhl as the Senior Editor, who also provided a full critique. Our decision has been reached after consultation between the reviewers. Based on these discussions and the individual reviews below, we regret to inform you that your work will not be considered further for publication in *eLife*.

The two re-reviews are very similar. While the new experiments improve the manuscript, they don\'t address the key question that was required, namely no mechanistic connection between the 2 isoforms, expression of RELMβ, and the phenotype. Perhaps the authors could perform an experiment (one suggested below) that would address this, but at this point the paper is not acceptable. If the authors do such an experiment, it would be reasonable to reconsider on appeal.

*Reviewer \#1:*

The authors have provided thoughtful responses to my comments, and they have done some new experiments that are useful. Nevertheless, I don\'t think they fully understood my point of view, and they only minimally addressed the key issue.

1\) The paper clearly represents an advance over published work, the experiments are well done, and it deserves publication. I don\'t dispute any of the authors\' responses about how their paper is advanced over previous work. However, the relevant question is how significant the advance is over previous work, particularly at the \"general interest\" level needed for publication in *eLife*. From my outside perspective, there is already evidence (perhaps considerable was too strong) that P1 acts as a tumor suppressor and that P2 acts an oncogene (less explicitly demonstrated, but the only reasonable way to explain how overproduction of HNF4α is oncogenic). The authors experiments are a nice and more explicit demonstration of the opposing roles of the P1 vs P2 forms, but I do not view this is as a major advance. Yes, the experimental systems are different and the experiments better, but the basic point is the same. For this reason, I (and the other Reviewer) thought that the basic opposing phenotypes were worth publishing, but not a sufficient advance for *eLife*.

2\) Because of point 1, I viewed it as important to have some mechanistic understanding of how the distinct HNF4α isoforms are linked to RELMβ. Of course, the primary finding (point 1) means that mice expressing these different isoforms have very different phenotypes and hence very different transcriptional profiles. Ultimately, this means that the different isoforms have different transcriptional effects, but profiling data per se provides no mechanistic information. Conversely, the previous knowledge that RELMβ is linked to colitis combined with the authors\' finding that RELMβ levels are increased in P2 mice does not indicate that this up-regulation is functionally important. It is entirely possible that a RELMβ derivative expressed at its normal level but unable to be induced by P2 would behave similarly to the wt (inducible) allele. To put it differently, one predicts that increased DSS sensitivity would depend on RELMβ no matter how once increased DSS sensitivity is achieved. So, again, there is no specific link between P2-overexpression and the RELMβ requirement for DSS sensitivity.

3\) The new ChIP experiments are useful, because they show that, in principle, the HNF4α isoforms could directly affect transcription of RELMβ. However, this does not really address the critical point, namely the differential behavior of the isoforms. Also, the focus on DNA-binding is possibly misplaced, as it is entirely possible that the distinction between the isoforms relates to transcriptional potential or interaction with other proteins (with differential transcriptional potential). I agree that artificial reporters with HNF4α sites is likely to be useless. But, what I imagined was an experiment with a reporter driven by a reasonably large segment of the RELMβ locus and co-transfection of the individual isoforms.

4\) The new barrier function experiments are nice on their own, but don\'t address mechanism related to the distinct isoforms. Again, the P1 vs. P2 cells have many differences, but those differences per se don\'t address any mechanistic understanding. The effects on barrier function and/or RELMβ could be very indirect consequences of the distinct HNF4α isoforms. By definition, the phenotypic differences caused by the distinct isoforms means that, at some level any property (molecular or overall phenotype) is differentially affected. In addition, the relationship of the P2 mice vs. other versions of DSS-induced colitis means that there are mechanistic similarities between those situations, but they don\'t address be basis of why P1 vs. P2 are different.

For these reasons, although the manuscript is improved, I still believe that the differences between the isoforms are phenomenological with limited mechanistic understanding, and their opposing roles in colitis and colitis-associated colon cancer are in accord with previous characterization as tumor suppressing and tumor promoting. As such, I think this paper will be of interest to specialists in HNF4α and colitis/colon cancer, and certainly worth publishing in a specialized journal, but it is unclear what findings are of more general significance.

*Reviewer \#2:*

This revised manuscript has been improved by the direct demonstration that RELMβ is an HNF4α target gene, and also the identification of the differential barrier function in the two isoform specific strains. However, the primary requirement for acceptance of this manuscript was clearly stated in the reviewing editor\'s decision: \"What is missing is a mechanistic connection between the 2 isoforms and expression of RELMβ. Thus, publication in *eLife* requires making such a mechanistic connection...\". As the authors acknowledge, this is a difficult, but important issue. Thus, despite the improvements, this revised manuscript has not effectively answered the primary question.

10.7554/eLife.10903.022

Author response

\[Editors' note: the author responses to the first round of peer review follow.\]

Both reviewers think that the paper is interesting and potentially appropriate for publication in eLife. However, though nicely demonstrated, the conclusion that the P1 form is tumor suppressing and the P2 form is oncogenic is insufficient for publication in eLife. What is missing is a mechanistic connection between the 2 isoforms and expression of RELMβ. Thus, publication in eLife requires making such a mechanistic connection, particularly showing that the P2 isoform, but not the P1 isoform, activates the RELMβ promoter through HNF4α sites. There are several possible options (reporter assays, ChIP, mutation of the site) that could be completed in the standard 2-month period (or slightly longer) since they are standard experiments. Ideally, it would be nice to show that P2-mediated regulation of RELMβ per se is critical in mice as mentioned by Reviewer 1, but this is likely to take too long and is not required. For your information, the full reviews are included below.

To reiterate the main finding of our work, we report for the first time that HNF4α isoforms driven by alternate promoters regulate colitis and colitis-associated colon cancer in an isoform-specific manner. We illustrate that P1-HNF4α attenuates, whereas P2-HNF4α accelerates, colitis and colitis-associated colon cancer, respectively. Our findings emphasize the importance of tracking the specific changes in P1- and P2-HNF4α isoforms under multiple pathological conditions, including inflammatory bowel disease (IBD) and colon cancer.

(We would also like to re-emphasize a more general relevance of our work. Many, if not most, human genes have more than one promoter and often those alternative promoter structures are conserved between human and mouse, as is that of HNF4α. And yet there is very little if any in vivo work on the effects of those alternative promoters. Our use of the HNF4α exon swap mice provides the ideal system with which to examine the effect of the different isoforms under physiological conditions of expression.)

In addition to elucidating an in vivo distinction between the HNF4α isoforms, we also identify the major mechanismby which α7HMZ mice have increased susceptibility to DSS-induced colitis -- namely that the mice have increased expression of the cytokine Relmβ -- and we provide strong proof of that mechanismby making double transgenic mice (RELMβ KO/α7HMZ). In this sense, we have already provided the mechanism for the main point of our paper but we understand the reviewers' desire to dig deeper and link the expression of Relmβ directly to the P2-HNF4α isoform (expressed in α7HMZ mice) but not the P1-HNF4α isoform.

While at first glance the simplest explanation may seem to be that HNF4α binds the RELMβ promoter in an isoform-specific manner, there are several reasons why this might not be the case. The DNA binding domains of P1- and P2- HNF4α are 100% identical (as indicated in [Figure 1A](#fig1){ref-type="fig"}) and we have already shown using a high throughput DNA binding assay in which we examined 250,000 unique sequences, as well as ChIPseq in HCT116 cells, that P1 and P2- HNF4α bind DNA with a very similar specificity both in vitroand in vivo(Vuong et al. 2015 MCB, PMID: 26240283) (We have also found nearly identical ChIPseq profiles of HNF4α in the livers of the isoform-specific mice, unpublished).

Nonetheless, it is true that we have observed some differences between the isoforms in DNA binding both in vitroand in vivo, so could the Relmβ promoter be one of those rare examples?

To address this issue we took two different approaches to examine both direct and indirect mechanisms responsible for the regulation of RELMβ by the HNF4α isoforms.

1\) Direct regulation of RELMβ expression by HNF4α

There are two reasons why we did not initially investigate further the possibility of HNF4α directly regulating the expression of the RELMβ gene. One, we did not detect any HNF4α ChIPseq peaks (or RNAseq signal) in the RELMβ promoter in the HCT116 cell line expressing either HNF4α2 (P1 isoform) or HNF4α8 (P2 isoform) (PMID: 26240283). Two, Verzi's group did not detect ChIPseq peaks for HNF4α in the CaCo2 cell line (PMID: 21074721). However, these negative results could be due either to the cell type (HCT116 cells do not express endogenous HNF4α and are considered to be stem cell like while Caco2 cells are a cancer cell line, albeit of an epithelial cell origin and they express endogenousl HNF4α) and/or technical issues (especially in terms of the Caco2 cells since we did not perform those experiments). The other possibility is that, in addition to HNF4α, other factors are needed to activate the expression of the RELMβ gene, such as CDX2, NFkB and STAT pathways, which are activated in response to bacteria (PMID:15576623). Neither the Caco2 nor the HCT116 cells were exposed to exogenous insults like LPS or cytokines for the ChIPseq experiments.

Therefore, prompted by the reviewer's comment, we ran the RELMβ promoter through the HNF4 Binding Site Scanner developed by our lab and identified several potential SVM sites (SVM = support vector machine learning, an algorithm that uses 1000's of experimentally verified binding sites for HNF4α to predict potential new binding sites (see Bolotin et al. 2010 Hepatology PMID:20054869 and <http://nrmotif.ucr.edu/>). We chose two regions to focus on which we refer to RELMβ Region 1 and Region 2. Region 1 has a high scoring SVM site (score of 1.94) and Region 2 has two lower scoring SVM sites (\~1.3). While typically we consider sites with scores of 1.5 or higher as good binders, we have also observed sites with lower scores (anything over 1.0) as binders as well. Region 2 also overlaps with NFkB, KLF4 and CDX2 sites, which have been shown to be involved in the activation of the RELMβ promoter in response to LPS in CaCo2 cells \[PMID:15576623\].

We performed HNF4α ChIP assays in the CaCo2 cell line and found that HNF4α binds the RELMβ promoter at both Region 1 and 2 (new [Figure 7A](#fig7){ref-type="fig"}). We have previously shown that the P2-isoform represents the majority of HNF4**α** expressed in Caco2 cells (\~90%), while the P1- isoform is expressed at a very low level (\~10%). (Chellappa et al. 2012 PNAS, PMID: 22308320, Figure S4B). We now show a similar distribution of the isoforms in the distal colon (see [Figure 3A](#fig3){ref-type="fig"}): by IB, most of the HNF4α is P2-HNF4α although by staining one can clearly see expression of P1-HNF4α at the top of the crypt ([Figure 1B, C, D](#fig1){ref-type="fig"}).

Even though we are unable to distinguish between the isoforms binding the RELMβ promoter in the Caco2 cells, it is safe to assume that since P2-HNF4α is the major isoform it is certainly binding.

\[We also performed parallel ChIP assays with LPS-treated Caco2 cells to recapitulate previously published results showing that LPS can activate the expression of RELMβ in Caco2 cells (PMID:14598255). However, we did not observe any significant, reproducible difference in HNF4α binding with LPS and only a modest, non-statistically significant increase in RELMβ expression, despite using the same range of published LPS concentrations (PMID:14598255). (RELMβ expression was not activated in the HCT116 cells by LPS so we did not attempt ChIP in that cell line.)\]

Therefore, our net results (presented in a new [Figure 7A](#fig7){ref-type="fig"}) are that endogenous HNF4α7 can indeed directly bind the endogenous RELMβ promoter in Caco2 cells in the absence of any additional signals, suggesting that HNF4α can indeed directly activate the expression of the RELMβ gene. Furthermore, we use HNF4 Binding Site Scanner to predict the DNA sequences to which HNF4α binds in the mouse promoter (new [Figure 7---figure supplement 1](#fig7s1){ref-type="fig"}).

Finally, we also attempted HNF4*α* ChIP of mouse colon tissue but due to technical difficulty (sample amount, sonication conditions, etc.) we could not get HNF4α ChIP to work in the allotted time frame (at this point we also had the Caco2 CHIP working so we decided to focus our efforts there). Furthermore, there was good reason to believe that even if we got the CHIP working in the colon, the desired result would not be forthcoming. In [Figure 2A](#fig2){ref-type="fig"} we show that in WT mice the level of expression of both isoforms of HNF4α (especially P2-HNF4α) is reduced upon DSS treatment. Therefore, this suggests that since RELMβ expression *increases* with DSS treatment that there is a mechanism other than HNF4α that is involved in the activation of the RELMβ promoter in vivo. We therefore felt that it was important to invest our resources and time to examine that mechanism as well. Those efforts are described below in (2).

2\) Indirect regulation of RELMβ expression by HNF4α isoforms

Since we demonstrated differential migration and ion transport in α1HMZ and α7HMZ mice ([Figure 5D and E](#fig5){ref-type="fig"}), alterations in RELMβ expression could also be due to other cellular processes altered by the HNF4α isoforms. It is well documented that intestinal permeability is an early event in IBD pathogenesis both in human patients and mouse models. Therefore, RELMβ expression and activation in the α7HMZ mice could be influenced by altered epithelial barrier function. Indeed, it has been shown previously that following DSS treatment there is an increase in intestinal permeability and RELMβ expression (PMID:16815164). These observations led us to hypothesize that altered barrier function could be an alternative mechanism for increased RELMβ expression in and susceptibility of α7HMZ mice to DSS.

To test this hypothesis we conducted several in vivo intestinal permeability assays using FITC-dextran. We found that untreated α7HMZ mice exhibit a moderate (trending towards significance) increased permeability / reduced barrier function compared to WT controls in both untreated and DSS-treated mice (new [Figure 7B](#fig7){ref-type="fig"}). We also observed that α1HMZ mice have improved barrier function post DSS treatment compared to α7HMZ (6d DSS + 3d recovery) ([Figure 7B](#fig7){ref-type="fig"}), supporting accelerated recovery as observed in [Figure 5E and F](#fig5){ref-type="fig"}.

This new finding prompted us to re-examine our microarray results for dysregulation of genes that could contribute to barrier function: we found several contenders, which are now presented in a new [Figure 7C](#fig7){ref-type="fig"}. In particular, an increase in *Il4i1* and *Il13ra2* expression in α7HMZ mice could contribute to increased RELMβ expression as reported previously (PMID: 19995957, PMID: 15340149). A decrease in cell adhesion and ion transport genes (Supplementary table S2C and S2D, respectively) could also contribute to increased paracellular permeability and loss of epithelial barrier. Indeed, we have recently shown that overexpression of P2-driven HNF4α (HNF4α8) in HCT116 cells increases cell migration, suggesting a loss of cell adhesion (PMID: 26240283). Loss of E-cadherin (*Cdh1),* a well-established target of HNF4α, aggravates colitis and impairs bacterial defense (PMID:25634675, PMID: 21179475): thus the 4-fold decrease in *Cdh1* expression observed in α7HMZ colons could contribute to impaired barrier function. It is also important to note that *Cdh1* slows epithelial cell migration, as we observe in

α7HMZ mice (PMID: 21179475). Finally, in a paper published just last week in Cell, the authors report that increased IL-18 signaling in intestinal epithelial cell disrupts barrier function (Nowarski et al. Cell, 2015). We found that *Il18r1* and *Il18rap* expression are increased in

α7HMZ mice, while *Il18bp*, a decoy receptor for *Il18* that attenuates downstream signaling is decreased in α7HMZ mice.

Taken togetherwe have now elucidated both a direct and indirect mechanism for the regulation of RELMβ (and hence colitis) mediated by the HNF4α isoforms. In the process we have added another characteristic to the list of phenotypic differences of the HNF4α isoform-specific mice (revised [Figure 7D](#fig7){ref-type="fig"}).

Reviewer \#1:

This paper presents useful data, but it belongs in a more specialized journal. There is already a considerable body of evidence indicating that the HNF4α isoforms are differentially regulated and have different functions. In particular, there is considerable evidence that the P1 form acts as a tumor suppressor. Also, over-expression of HNF4α is oncogenic despite the P1 form, suggesting that P2 acts as an oncogene. The authors nicely test this by generating mice that can only express either the P1 or P2 isoforms and assessing various phenotypes including gene expression profiles and colitis susceptibilities, the authors significantly improve the understanding of the distinct roles of these isoforms. To this non-expert, the experiments generally seem fine with clear results.

We thank the reviewer for finding the manuscript of functional relevance and for insightful comments. We agree with the reviewer that it is now established that P1-HNF4α acts as tumor suppressor in the liver but as we indicate in the Introduction the role of P2-HNF4α in colon cancer is ambiguous with the only work directly addressing the issue being our paper that was published in Oct 2015 in MCB (PMID:26240283). That work uses only HCT116 cells in a xenograft model and it does not explore colitis or colitis-associated colon cancer in an in vivo model as we do here.

There is already a considerable body of evidence indicating that the HNF4α isoforms are differentially regulated and have different functions.

We must respectfully disagree with the reviewer on this point. Having originally cloned HNF4α 25 years ago, we are well aware of the HNF4α literature. Indeed, it has only been recently that a role for HNF4α in cancer and the colon in general has begun to be investigated, as we summarize in the Introduction. The role of the HNF4α isoforms had not been addressed under any pathological conditions in vivo until the development of monoclonal antibodies to the HNF4α isoforms in 2006 (PMID:16400631). In this paper the authors showed for the first time that expression of P1-HNF4α but not P2-HNF4α is lost in colon cancer patients. However, they did not address either the mechanism responsible for the isoform-specific loss of HNF4α nor the functional relevance the isoforms. In fact, it was the observations in this paper that prompted us to investigate the mechanism responsible for the differential loss, which we did in our 2012 PNAS paper (PMID: 22308320) where we showed HNF4α isoform-specific effects of Src tyrosine kinase in human colon cancer.

However, while the PNAS paper confirmed the importance of tracking changes in individual HNF4α isoforms in colon cancer (and provided the mechanism for the isoform-specific down regulation), it did *not* address the function of the isoforms in the colon as we do nowin the current work. In fact, this manuscript is only the second publication on the exon swap (HNF4α isoform-specific) mice, which were created by one of us (NB). The first paper (PMID:16498401) examined the liver of the mice under fed and fasted conditions and proved for the first time that the AB domain of HNF4α has a function in vivo. It did not, however, examine the colon or intestines. Finally, before 2006 there were a couple of papers on the function of the HNF4α isoforms using cell based systems (including one that FMS is co-author on) but as relevant as that work was at the time, it did not examine the isoforms in vivo nor in a global fashion. Indeed, most papers on HNF4α do not even distinguish which isoforms are being examined, which has led to some of the confusion in the field.

In contrast to the paucity of literature on the HNF4α isoforms, despite their importance, there are \>1000 publications in Pubmed that come up with "progesterone receptor and isoforms" and yet we still do not understand the difference in the function of the PR isoforms, even though it is well established that they too are dysregulated in cancer. Furthermore, the PR isoforms have not been examined using isoform-specific mouse models as we do here for HNF4α.

Thus, it is a bold overstatement to say that there is a considerable body of evidence on the HNF4α isoforms. Indeed, if we felt that all the questions had been addressed in this regard we would not be spending our time and effort on the topic.

However, the differences between the isoforms are phenomenological with limited mechanistic understanding, and their opposing roles in colitis and colitis-associated colon cancer are in accord with previous characterization as tumor suppressing and tumor promoting. As such, I think this paper will be of interest to specialists in HNF4α and colitis/colon cancer, but it is unclear what findings are of more general significance.

Again, we must respectfully disagree. As described above we did provide a mechanism via RELMβ in our first submission. We have now added two additional mechanisms outlined above in terms of direct binding of HNF4α to the RELMβ promoter as well as alterations in barrier function, along with potential genes that could be responsible for the effects.

Furthermore, colitis is not necessarily the same as colon cancer (although it can lead to it), and hence functional roles of tumor suppressing and tumor promoting may not apply.

Indeed, we examined the effect of chronic DSS treatment in α7HMZ mice as we thought that it would increase tumor load. However, as noted in the text, we found that despite the sensitivity of the α7HMZ mice to colitis and AOM+DSS, DSS treatment alone was not sufficient to induce tumor formation in α7HMZ mice.

Except for a recent paper on the role of P2-HNF4α in gastric cancer (PMID: 25410163), we are not aware of any other literature describing an oncogenic role for P2-HNF4α (Our 2015 MCB paper just shows that P2-HNF4α is permissive of tumor growth, it does not accelerate it.)

*It is already known that loss of RELMβ causes resistance to colitis. The new finding here is this gene is up-regulated by the P2 form, which of course also stimulates colitis. So, the knock-out result is largely expected. Moreover, the conclusion that P2-mediated up-regulation of RELMβ is important is not really tested. The correct experiment would be to knock out HNF4 sites that are required for the up-regulation of RELMβ and show that this blocks colitis. Alternatively, some other manipulation that reduces RELMβ levels to the uninduced level. To put it differently, one has to show that the regulation of RELMβ is important, not just the gene itself which is already known. I realize this is a fair amount of work.*

Prior knowledge that RELMβ contributes to colitis and our finding of increased RELMβ in α7HMZ mice areexactlywhat prompted us to addresswhether this cytokine contributes to increased susceptibility to DSS-induced colitis. Just because RELMβ expression was upregulated, it did not necessarily have to be the case that it was a major player in α7HMZ susceptibility. Fortunately for us, after taking a year to generate the double transgenic mouse and another year to analyze them, upregulation of RELMβ did turn out to be a causal effect.

Please see our response above about the two mechanisms that we have now elucidated for the upregulation of RELMβ in α7HMZ mice -- direct regulation by P2-HNF4α as evidenced in a ChIP assay and indirect regulation via altered barrier function.

In the direct mechanism we identify several putative HNF4α binding sites and show that P2- HNF4α can indeed directly bind the RELMβ promoter (new [Figure 7A](#fig7){ref-type="fig"} and [Figure 7---figure supplement 1](#fig7s1){ref-type="fig"}). Therefore, knocking out of an HNF4α binding site is not so simple -- at least 3 sites would most likely have to be deleted.

Reviewer \#2:

HNF4α expression in the gut has been linked to both colitis and colon cancer. Chellapa et al. describe strikingly differential effects of distinct isoforms of HNF4α in the gut. Expression of the P2 promoter isoform only results in increased sensitivity to DSS and increased tumorigenesis in an AOX/DSS model, while opposite results are observed with mice that express only the P1 isoforms. Within the context of nuclear receptor function, it is well known that there are multiple isoforms of many NRs, but they are generally not distinguished functionally. Thus, this represents a particularly clear example of delineation of distinct functions of different isoforms. This observation might be of more limited interest, but clear mechanistic information is provided by the demonstration that RELMβ is overexpressed in the DSS sensitive P2-specific mice, and that doubly mutant P2 specific/RELMβ knockout mice are resistant to the increased sensitivity to DSS.

We thank the reviewer for his in-depth understanding of our manuscript and its relevance to both the nuclear receptor field and colon pathology.

One question raised by these results is whether the effects of the different isoforms on RELMβ expression are direct or indirect, and particularly whether the distinct isoforms have distinct direct effects on RELMβ expression. This study would be further strengthened if relatively straightforward RELMβ promoter cotransfections showed such effects, or if other strategies could document differential promoter occupancy.

In response to the reviewers' comments, as described above, we performed a ChIP assay and found that endogenous HNF4α in a human colon epithelial cell line (Caco2) can bind the endogenous RELMβ promoter directly. We also found that there are predicted HNF4α binding sites in the same region of mouse RELMβ gene (see new [Figure 7A](#fig7){ref-type="fig"}, [Figure 7---figure supplement 1](#fig7s1){ref-type="fig"}). This makes RELMβ a direct target of HNF4α.

We do not feel that co-transfection assays would be any more informative than the expression profiling (and now ChIP). In our experience in working with HNF4α for the last 25 years, putting a promoter with an HNF4α binding site in front of a luciferase gene and co-transfecting in HNF4α will result in activation of the promoter, typically in direct relation to the affinity that HNF4α has to the site in vitro.

At this point, as mentioned abovein the overall response to the editor, we are unable to determine whether P2-HNF4α but not P1-HNF4α can bind the RELMβ promoter in vivo. However, also as described above, we predict that P1-HNF4α as well as P2-HNF4α would be able to bind the RELMβ promoter based on our recently published work in MCB (PMID: 26240283) and that different co-regulators and transcription factors recruited to the promoter confer the specificity. We do find the issue of differential regulation despite similar DNA binding to be a very interesting and important one. We are trying to pursue it in the liver where there is much more tissue available but it is not a trivial issue and definitely beyond the scope of the current work.

Complicating the situation is the issue of which isoforms are present during DSS treatment when RELMβ expression is elevated. In [Figure 2A](#fig2){ref-type="fig"} we show that both P1- and P2-HNF4α are down regulated at 6 days DSS (which would make ChIP even more difficult if not impossible). In [Figure 4D](#fig4){ref-type="fig"} we also show that in α7HMZ mice there is an upregulation of P2-HNF4α at 6 days DSS. While the reason for this increase remains unknown it could nonetheless explain the upregulation of RELMβ at that time point in those mice compared to WT mice -- there is simply more of P2-HNF4α present. It also suggests that other factors are at play in regulating RELMβ expression.

As described above, we also now elucidate an indirect, as well as direct, mechanism of regulation of RELMβ. We show using FITC-dextran studies that the α7HMZ mice have a lower barrier function than WT mice, which could allow more bacteria to cross the barrier and hence activate expression of the RELMβ gene.

In summary, we believe that, there could be two different mechanisms occurring. In the untreated mice the lower basal level of barrier function in α7HMZ mice could lead to increased signaling from bacteria that cross the barrier and hence activation by CDX2 (PMID:15576623) even though there is no difference in the amount of HNF4α that is present compared to WT mice (see [Figure 3A](#fig3){ref-type="fig"}). While in the DSS-treated mice, in addition to even lower barrier function and hence more bacteria presumably crossing the barrier, in the α7HMZ mice there is more HNF4α present than in the WT mice which could also contribute to greater RELMβ expression.

\[Editors' note: the author responses to the re-review follow.\]

The two re-reviews are very similar. While the new experiments improve the manuscript, they don\'t address the key question that was required, namely no mechanistic connection between the 2 isoforms, expression of RELMβ, and the phenotype. Perhaps the authors could perform an experiment (one suggested below) that would address this, but at this point the paper is not acceptable. If the authors do such an experiment, it would be reasonable to reconsider on appeal.

*Reviewer \#1:*

*The authors have provided thoughtful responses to my comments, and they have done some new experiments that are useful. Nevertheless, I don\'t think they fully understood my point of view, and they only minimally addressed the key issue.*

1\) The paper clearly represents an advance over published work, the experiments are well done, and it deserves publication. I don\'t dispute any of the authors\' responses about how their paper is advanced over previous work. However, the relevant question is how significant the advance is over previous work, particularly at the \"general interest\" level needed for publication in eLife. From my outside perspective, there is already evidence (perhaps considerable was too strong) that P1 acts as a tumor suppressor and that P2 acts an oncogene (less explicitly demonstrated, but the only reasonable way to explain how overproduction of HNF4α is oncogenic). The authors experiments are a nice and more explicit demonstration of the opposing roles of the P1 vs P2 forms, but I do not view this is as a major advance. Yes, the experimental systems are different and the experiments better, but the basic point is the same. For this reason, I (and the other Reviewer) thought that the basic opposing phenotypes were worth publishing, but not a sufficient advance for eLife.

We thank the reviewer for acknowledging the importance of the work but for the record we respectfully disagree that we had done nothing more than prove our point with more convincing and relevant systems. In addition to showing differential in vivo effects of P1-HNF4α and P2-HNF4α on colon cancer, we also showed that they play different roles in colitis as well as barrier function, RELMβ expression and different distribution within the tissue (none of this had been shown previously).

While perhaps the reviewer does not consider that these results with clinical implications are of sufficient importance for *eLife*, we would argue that showing how disruption of the balance of splice variants in vivo can result in disease is an appropriate topic for *eLife*, especially considering that \>50% of human genes have alternative promoters and \>90% of human genes undergo alternative splicing even though for most genes we know next to nothing about the impact of those splice variants.

In addition to parsing the in vivo role of the HNF4α isoforms in the colon, colitis and colon cancer, to our knowledge this work is also the first to document a change in promoter usage/transcript variant along the colonic crypt that results in an induction of colitis and/or colon cancer. Changes in expression of different genes along the crypt are well documented (e.g., APC/b-catenin, Ki67, NKCC1) but on 4/30/16 there are only 10 hits in Pubmed in a search for "(colonic crypt) AND alternative splicing," including some where alternative splice variants are associated with colon cancer (e.g., CD44) but none that show the change in variants actually *induce* colon cancer or colitis susceptibility, as we show here for HNF4α.

A search of Pubmed for "exon swap" yields no papers published on this topic in *eLife*. There are only 4 papers published in *eLife* on "alternative promoter" (none discussing the generation of different transcript variants from those promoters) and only 21 out of 2360 total papers in *eLife* on "alternative splicing". These numbers indicate that as important as alternative splicing and alternative promoter usage are, they remain highly understudied.

2\) Because of point 1, I viewed it as important to have some mechanistic understanding of how the distinct HNF4α isoforms are linked to RELMβ. Of course, the primary finding (point 1) means that mice expressing these different isoforms have very different phenotypes and hence very different transcriptional profiles. Ultimately, this means that the different isoforms have different transcriptional effects, but profiling data per se provides no mechanistic information. Conversely, the previous knowledge that RELMβ is linked to colitis combined with the authors\' finding that RELMβ levels are increased in P2 mice does not indicate that this up-regulation is functionally important. It is entirely possible that a RELMβ derivative expressed at its normal level but unable to be induced by P2 would behave similarly to the wt (inducible) allele. To put it differently, one predicts that increased DSS sensitivity would depend on RELMβ no matter how once increased DSS sensitivity is achieved. So, again, there is no specific link between P2-overexpression and the RELMβ requirement for DSS sensitivity.

We now show that the HNF4α isoforms differentially activate the RELMβ promoter in a revised [Figure 7](#fig7){ref-type="fig"} using the previously suggested luciferase assays. The results show that P2-HNF4α does indeed activate the RELMβ promoter more potently than P1-HNF4α. We humbly thank the Reviewer for insisting that we perform this experiment. (Please see specifics below.)

To address the next issue regarding the mechanism by which the HNF4α isoforms activate transcription in a differential fashion, we performed a RIME assay in which we identify in a global, unbiased fashion the proteins that the isoforms interact with in the colon. As we predicted from our unpublished work in the liver, we found \>100 differentially interacting proteins which we now present in a revised [Figure 5](#fig5){ref-type="fig"}. Any one of these differentially interacting proteins could have an impact on HNF4α transactivation. For example, we found that Src tyrosine kinase specifically interacts with P1-HNF4α but not P2-HNF4α in mouse colon. This finding validates our approach as it is consistent with our 2012 PNAS work in which we show that in cell-based assays Src specifically phosphorylates P1-HNF4α and causes a decrease in protein stability as well as nuclear localization and transactivation potential. In this single experiment in [Figure 5C](#fig5){ref-type="fig"} we now add to the Src story more than a dozen other kinases, phosphatases and other proteins that could impact HNF4α transactivation.

We respectfully disagree that there is no specific link between "P2-overexpression" (expression in different compartment of the crypt would be more accurate) and the RELMβ requirement for DSS sensitivity. It is not clear to us how the double transgenic RELMβ KO and α7HMZ exon swap mice that lose the remarkable lethality to DSS does not prove the necessity of RELMβ. It is true that α7HMZ may promote colitis through multiple pathways, but these are evidently all ultimately *dependent* on RELMβ, since deleting RELMβ abrogates α7HMZ-induced lethality.

It is not clear what is meant by the following, but we will address it to the best of our ability:

"It is entirely possible that a RELMβ derivative expressed at its normal level but unable to be induced by P2 would behave similarly to the wt (inducible) allele. To put it differently, one predicts that increased DSS sensitivity would depend on RELMβ no matter how once increased DSS sensitivity is achieved."

The KO removed all exons in the *Retnlb* gene. We realize that many different factors, in addition to HNF4α, affect RELMβ expression. Indeed, that is why we took the approach of looking at the effect of the HNF4α isoforms on barrier function as that would be a starting point of multiple pathways to RELMβ expression.

We have now added to the barrier function pathway, the pathway of a7HMZ directly activating the RELMβ promoter (see below re revised [Figure 7](#fig7){ref-type="fig"}).

3\) The new ChIP experiments are useful, because they show that, in principle, the HNF4α isoforms could directly affect transcription of RELMβ. However, this does not really address the critical point, namely the differential behavior of the isoforms. Also, the focus on DNA-binding is possibly misplaced, as it is entirely possible that the distinction between the isoforms relates to transcriptional potential or interaction with other proteins (with differential transcriptional potential). I agree that artificial reporters with HNF4α sites is likely to be useless. But, what I imagined was an experiment with a reporter driven by a reasonably large segment of the RELMβ locus and co-transfection of the individual isoforms.

To address the transactivation potential of HNF4α isoforms on RELMβ promoter we performed luciferase assays on RELMβ reporter constructs containing up to 800 bp of promoter sequence as well as HNF4α binding sites ([Figure 7---figure supplement 1D](#fig7s1){ref-type="fig"}) that we identified recently in silico and in ChIP assay ([Figure 7A](#fig7){ref-type="fig"}). We co-transfected HNF4α isoforms in LS174T cell line with RELMβ reporter constructs and we found that P2-HNF4α activates RELMβ promoter significantly better than P1-HNF4α (new [Figure 7B](#fig7){ref-type="fig"}).

Furthermore, we also knocked down the endogenous expression of HNF4α isoforms in LS174T cell line and found that knock down of P2-HNF4α significantly decreases RELMβ promoter activity in the luciferase assay compared to siP1-HNF4α (new [Figure 7 ---figure supplement 1E](#fig7s1){ref-type="fig"}). These experiments show that both HNF4α isoforms regulate RELMβ promoter but P2-HNF4α is stronger transactivator than P1-HNF4α. On the other hand P2-HNF4α does not activate ApoB promoter well compared to P1-HNF4α (new [Figure 7 ---figure supplement 1F](#fig7s1){ref-type="fig"}), indicating that there are promoter-specific effects of the HNF4α isoforms, consistent with the gene expression arrays. The findings are also consistent with those in the revised [Figure 5](#fig5){ref-type="fig"} where we show that the HNF4α isoforms interact with different proteins, which could result in differential transactivation potential.

4\) The new barrier function experiments are nice on their own, but don\'t address mechanism related to the distinct isoforms. Again, the P1 vs. P2 cells have many differences, but those differences per se don\'t address any mechanistic understanding. The effects on barrier function and/or RELMβ could be very indirect consequences of the distinct HNF4α isoforms. By definition, the phenotypic differences caused by the distinct isoforms means that, at some level any property (molecular or overall phenotype) is differentially affected. In addition, the relationship of the P2 mice vs. other versions of DSS-induced colitis means that there are mechanistic similarities between those situations, but they don\'t address be basis of why P1 vs. P2 are different.

RIME analysis in a new [Figure 5C](#fig5){ref-type="fig"} addresses this issue as well as it can be addressed given the current technology. The only thing that would be left to do is determine which of the 100+ differentially interacting proteins is relevant for each of the 100+ HNF4α target genes. This is clearly beyond the scope of any single paper, regardless of the journal.

For these reasons, although the manuscript is improved, I still believe that the differences between the isoforms are phenomenological with limited mechanistic understanding, and their opposing roles in colitis and colitis-associated colon cancer are in accord with previous characterization as tumor suppressing and tumor promoting. As such, I think this paper will be of interest to specialists in HNF4α and colitis/colon cancer, and certainly worth publishing in a specialized journal, but it is unclear what findings are of more general significance.

We thank the reviewer for acknowledging improvements to the manuscript and are very appreciative of his/her time and effort in reviewing it. We sincerely hope that we have now provided sufficient evidence to show that the HNF4α isoforms activate RELMβ and other genes in a differential fashion due to unique sets of interacting proteins, and that we have convinced him/her that our manuscript is worthy of publication in *eLife*.

Reviewer \#2:

This revised manuscript has been improved by the direct demonstration that RELMβ is an HNF4α target gene, and also the identification of the differential barrier function in the two isoform specific strains. However, the primary requirement for acceptance of this manuscript was clearly stated in the reviewing editor\'s decision: \"What is missing is a mechanistic connection between the 2 isoforms and expression of RELMβ. Thus, publication in eLife requires making such a mechanistic connection...\" As the authors acknowledge, this is a difficult, but important issue. Thus, despite the improvements, this revised manuscript has not effectively answered the primary question.

We have addressed the direct regulation of RELMβ by HNF4α isoforms using a luciferase reporter assay, as requested, and show that P2-HNF4α is a stronger transcriptional activator of RELMβ promoter compared to P1-HNF4α in a revised [Figure 7](#fig7){ref-type="fig"} as well as a new panel in the supplement to [Figure 7](#fig7){ref-type="fig"}.

We also addressed the issue of the mechanism by which the HNF4α isoforms might differentially regulate gene expression by showing in a RIME (aka proteomics) assay in a revised [Figure 5](#fig5){ref-type="fig"} that the HNF4α isoforms interact with different proteins in vivo, particularly signaling factors and RNA binding proteins that could alter transactivation activity.

From our Response to Reviewer \#1:

To address the next issue of regarding the mechanism by which the HNF4α isoforms activate transcription in a differential fashion, we performed a RIME assay in which we look in vivo at what proteins the isoforms are interacting with. As we predicted from our unpublished work in the liver, we found \>100 differentially interacting proteins which we now present in a revised [Figure 5](#fig5){ref-type="fig"}. Any one of these differentially interacting proteins could have an impact on HNF4α transactivation. For example, we found that Src tyrosine kinase specifically interacts with P1-HNF4α but not P2-HNF4α in mouse colon. This finding validates our approach as it is consistent with our 2012 PNAS work in which we show that in cell-based assays Src specifically phosphorylates P1-HNF4α and causes a decrease in protein stability as well as nuclear localization and transactivation potential. In this single experiment in [Figure 5C](#fig5){ref-type="fig"} we now add to the Src story more than a dozen other kinases, phosphatases and other proteins that could impact HNF4α transactivation.

[^1]: Institute for Diabetes, Obesity, and Metabolism, Department of Physiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, United States.
